Tactile Systems Technology (Minneapolis, MN)

 Tactile Systems Technology  (Minneapolis, MN; no SBIR), which has developed a high-tech wrap to treat swollen limbs caused by lymphodema and other ailments, has raised $11.8M. [Minneapolis / St. Paul Business Journal, Oct 30, 07]

Talecris Biotherapeutics (RTP, NC)

Biopharmaceutical company Talecris Biotherapeutics Holdings Corp (RTP, NC; no SBIR) gained 11% in its initial public offering, the first pharmaceutical IPO to perform well in two years. ..  makes plasma-derived treatments for diseases, including hemophilia and pediatric HIV infections. The company has years of profits under its belt; in the first six months of the year, its net revenue rose 20% to $735 million, and net income hit $117 million. [Wall Street Journal, Oct 2, 09]

Taligen Therapeutics (Greenwood Village, CO)

Taligen Therapeutics (Cambridge, MA; $1M SBIR (in Colorado)) raised $26 million of its projected $64.9 million funding round, according to federal documents. Taligen CEO Abbie Celniker confirmed that the funding is part of its Series B round and will be spent on drug development.    ....  new protein drugs to treat inflammation and related diseases.  [Marc Songini, Mass High Tech, May 12, 09]

Nearer the Action. biotech start-up Taligen Therapeutics (Greenwood Village, CO; $1M SBIR) is moving its headquarters to Cambridge MA and hired a local Novartis AG (Swiss giant) executive to run the company, .... with just eight employees, but recently raised $65 million in VC  [Boston Globe, Jul 24, 08].

Talima Therapeutics (Santa Clara, CA)

Talima Therapeutics (Santa Clara, CA; no SBIR)  raised $19M in a second funding round. .. founded in 2005, has developed a micro-implant technology to enable site-specific drug delivery designed to minimize the side effects of systemic drugs [San Jose Mercury News, Jun 6]

Tanox (Houston, TX)

Tanox (Houston, TX; $1.5M SBIR) is being bought by Genentech. Founder CEO Nancy Chang of the 20-year-old biotech company who was a professor at the Baylor College of Medicine says that Pharmaceutical companies are realizing that it’s so expensive to discover new drugs that they’re relying more and more on biotechs for the discovery, development and concept phases. [Southwest Economy, Dallas Federal Reserve, M/A07]  Formed in 1986 and first SBIR in 1988 and last SBIR in 2000. It's a poster story SBIR - seed money for starting real innovation followed by private capital - instead of steadily feeding market-dead beneficiaries.  Chang notes that the U.S. is still the one place where people value creativity. There are savvy investors and hard-driving entrepreneurs in the U.S. who are willing to invest their money, time and expertise on innovative ideas in new drug development.

Biotech Tanox (Houston, TX) will sell itself to Genentech for $919 million. [Houston Chronicle, Jan 16] SBIR $1.4M until Y2K.

Tanox up 45%  on being acquired by Genentech.  [Nov 10, 06] $1.4M SBIR in the 1990s.

Tarari (San Diego,CA)

Tarari (San Diego,CA; no SBIR) is being sold to LSI for $85M cash – giving Tarari a large parent to support the roll out of chips that ward off computer viruses. a five-year-old company that has raised $42 million in venture capital, has been selling its chips for about two years, with customers including Cisco Systems and Secure Computing. [San Diego Union Tribune, Sep 6]

Targacept

Targacept up 16% [Oct 16, 09] company released the complete results of a midstage study on its drug to treat a major depressive disorder. Analysts called the results "eye popping." [Wall Street Journal, Oct 17, 09]

Targacept down 10% [Oct 12, 09]

Targacept, up 772%, led the pack in percentage gain for the second quarter. Osiris had the tenth worst quarter at -50%. [Wall Street Journal, Oct 1, 09]

Targacept down 11% [Oct 1, 09]

Targacept up 137% [Jul 15, 09]  company's treatment for major depressive disorder was shown effective and safe in midstage clinical trials, paving the way for latestage trials and discussions with the Food and Drug Administration for approval. [Wall Street Journal, Jul 16]

Targacept up 28% [Jul 8, 09] AstraZeneca P.L.C. said it had agreed to make a $10 million milestone payment to Targacept because the two companies plan to conduct further development of AZD3480. ... would begin Phase IIb studies on the drug to treat attention deficit/hyperactivity disorder.   [Philadelphia Inquirer, Jul 8, 09]

Targacept up 13% [Jun 24, 09]

Targacept down 12% [May 1, 09]

Targacept  up 14% [Apr 29, 09]

Targacept  down 11% [Apr 27, 09]

Targacept  down 11% [Apr 23, 09]

Targacept  up 10% [Apr 15, 09]

Targacept up 13%% [Apr 2, 09]

Targacept  down 17% [Mar 27, 09]

Targacept up 27% [Mar 12, 09]

Targacept  down 19% [Mar 11, 09]

Targacept up 24% [Mar 10, 09]\

Targacept  down 11% [Mar 5, 09]

Targacept down 17% [Feb 25, 09]

Targacept  up 35% [Feb 24, 09]

Targacept down 20% [Feb 10, 09]

Targacept   up 15% [Feb 3, 09]

Targacept   up 20% [Feb 2, 09]

Targacept  down 16% [Jan 29, 09]

Targacept  up 15% [Jan 28, 09]

Targacept down 22% [Jan 22, 09]

Targacept up 28% [Jan 21, 09]

Targacept down 16% [Jan 9, 09]

Targacept up 11% [Jan 8, 09]

Targacept up 19% [Dec 31, 08]

Targacept down 17% [Dec 23, 08] 

Targacept up 24% [Dec 22, 08]

Targacept up 11% [Dec 12, 08]

Targacept up 48% [Dec 8, 08]

Targacept   up 38% [Dec 2, 08]

Targacept down 25% [Nov 17, 08]

Targacept down 19% [Nov 14, 08]

Targacept up 15% [Nov 13, 08]

Targacept up 21% [Nov 7, 08]

Targacept down 13% [Nov 6, 08]

Targacept down 13% [Nov 5, 08]

Targacept up 15% [Oct 31, 08]

Targacept up 11% [Oct 30, 08]

Targacept up 17% [Oct 28, 08]

Targacept down 11% [Oct 17, 08]

Targacept up 50% [Oct 16, 08]

Targacept down 35% [Oct 15, 08]

Targacept  up 87% [Oct 10, 08]

Targacept down 36% [Oct 9, 08]

Targacept down 11% [Oct 8, 08]

Targacept down 14% [Oct 7, 08]

Targacept down 11% [Oct 8, 08]

Targacept down 14% [Oct 7, 08]

Targacept up 18% [Sep 25, 08]

Targacept up 37% [Sep 18, 08]

Targacept  down 29% [Sep 17, 08]

Targacept  down 31% [Sep 16, 08] on inconclusive study results.

Targacept up 11% [Sep 10, 08]

Targaceptup 11% [Jul 30, 08]

Targacept kept climbing the hill, up another 15%.  [Nov 3, 06] Somebody knows something.

Targacept up 14% [Nov 2, 06]

Targ-Anox (Boston, MA)

A handful of local life sciences companies have sprung to life over the past several months, in spite of a venture capital landscape that has sometimes looked windswept and barren. ... Companies that have successfully launched in this environment have powerful allies and a frugal mindset. Several are going after a platform that could target several diseases. Analysts say this approach gives the company several shots at profitability, making them more attractive to investors. ... Last week, Acetylon Pharmaceuticals (Cambridge, MA; no SBIR) announced its official launch with $7.25 million from private investors ...  One company that did raise money from a traditional venture firm is Targ-Anox (Boston, MA; no SBIR). The company coalesced around technology discovered by Brigham and Women’s Hospital chief of medicine Joseph Loscalzo.  [Mass High Tech, Aug 14, 09]

Targanta (Cambridge, MA)

Targanta Therapeutics  will be acquired by New Jersey’s The Medicines Co. in a deal that could be worth about $133.35 million, according to The Medicines Co.

Struggling Cambridge biotech Targanta Therapeutics  is being bought for about $42 million by the Medicines Co., a New Jersey drug company. [Boston Globe, Jan 13, 09]

scientists at Targanta Therapeutics spent more than three years developing a powerful antibiotic to kill deadly bacteria.  But these days, instead of fighting bacteria, the company is fighting for its own life, cutting jobs and watching its stock languish. Last month, the Food and Drug Administration rejected Targanta's first product, a drug called oritavancin. Regulators asked Targanta to conduct a new clinical trial that could cost another $40 million. Running out of money, Targanta said it would lay off 75 percent of its staff of 120, spread across Indiana, Massachusetts and Canada. Now the company is scrambling to find more money, a daunting task in the industry's toughest fundraising climate in 15 years. [Indianapolis Star, Jan 11, 09]

Targanta Therapeutics said today that it will have to conduct an additional study on the developing antibiotic oritavancin in order to satisfy a Food and Drug Administration review.  [Boston Globe, Dec 9, 08]

Targanta Therapeutics plunged, a day after a panel of government experts voted against the benefits of the company's antibiotic.  Yesterday the FDA's panel of infection experts voted 10 to 8 against the overall safety and effectiveness of the company's injectable drug, called oritavancin.  Shares 81% in midafternoon trading.  [Boston Globe, Nov 20, 08]

Targanta Therapeutics up 40% after federal regulators posted a favorable review of the company's antibiotic, ahead of a meeting to assess the product later this week.  [Boston Globe, Nov 18, 08]

Targanta Therapeutics (Cambridge MA) went public [Oct 10, 07] for only $57M, below its planned $90M.

Antibiotics developer Targanta Therapeutics (Cambridge MA, no SBIR) priced its $90M IPO for some still future emergence.  [Sep 28, 07]

Targanta Therapeutics (Cambridge MA; no SBIR). has launched a clinical trial to study less frequent dosing regimens of its lead antibiotic, four months after announcing plans for an IPO.  [Mass High Tech, Sep 14]

Targanta (Cambridge MA, no SBIR)got $70M in VC money to develop a powerful antibiotic from a microbe discovered in Haitian dirt.  The intellectual property comes from Eli Lily which exited the business to focus on other diseases.  [Stephen Heuser, Boston Globe, Feb 9]

Targeted Genetics

Targeted Genetics, a 21-year-old Seattle biotechnology company that's been struggling in recent years, said it plans to deregister its stock and cease filing [SEC] reports.  [Seattle Times, Jan 14, 10]

Targeted Genetics has struck a $7 million technology deal with Massachusetts-based Genzyme, extending the life of a cash-strapped Seattle biotechnology company.  [Seattle Times, Sep 9, 09]

Targeted Genetics said it’s received a delisting letter from the NASDAQ Stock Market, saying the biotech isn’t in compliance with the market’s minimum listing requirements. ... hasn’t maintained a minimum of $2.5 million in shareholder’s equity [Puget Sound Business Review, Jul 29, 09]

Targeted Genetics reported that its current funds can't keep the company running beyond next month  [Seattle Times, Jul 25, 09]

Targeted Genetics  said it’s rapidly running out of cash and if it doesn’t find some more in a hurry, it could go out of business or declare bankruptcy. [Puget Sound Business Journal, May 8, 09]

Targeted Genetics said it’s made a couple of deals that it said should provide it with enough money “to support operations through the first half of 2009.” [Puget Sound Business Journal, Mar 2, 09]

Targeted Genetics said it has cut its payroll by 25 percent through layoffs and senior executive pay cuts, and has shifted its research efforts in a bid to survive a cash crunch. [Angel Gonzalez, Seattle Times, Dec 3,08]

Nasdaq warned Targeted Genetics that its stock could be delisted if it doesn't rise above $1 for at least 10 consecutive days within six months [Seattle Times, Apr 26, 08]

Targeted Genetics lost $16M for the year, only half its 2006 loss of $33M.  [Seattle Times, Mar 26]

FDA cleared Targeted Genetics to restart its gene-therapy trial for rheumatoid arthritis after an investigation indicated the treatment did not contribute to the death of an Illinois woman. [Angel Gonzalez, Seattle Times, Nov 26]

Targeted Genetics up 11% [Oct 10, 07]

Targeted Genetics (one Phase 2 SBIR) put its leading clinical trial (of its inflammatory arthritis drug) on hold yesterday after one of the enrolled patients became seriously ill. ... also working on therapies for human immunodeficiency virus, congestive heart failure and Huntington's disease [Seattle Times, Jul 25]

Targeted Genetics completed a private-equity placement of $17.8M. [Seattle Times, Jun 29]

Targeted Genetics up 66% on news of making a profit of $800K even though a yearly loss of $34M.  [Mar 29, 07]

Targeted Genetics fell 20% on news of raising $8.7M by private placement. [Jan 8, 07]

Targeted Genetics   shot up more than 52 percent in trading Monday, but company officials say they don't know why the stock price skyrocketed.

Targeted Genetics up 26% after losing less than last year. [Nov 10, 06]

Targeted Genetics rocketed up a third on news of a debt deal. [Nov 7, 06]

Targeted Growth (Seattle WA)

With the two Montana Senators and governor smiling, Targeted Growth (Seattle WA; no SBIR), a renewable energy bioscience company, and Green Earth Fuels (Houston, TX; no SBIR), a vertically integrated renewable biodiesel energy company, announce the formation of a joint venture called Sustainable Oils, Inc. (www.susoils.com) at a press conference today. The new venture will produce and market up to 100 million gallons of Camelina-based biodiesel by 2010  [Targeted Growth press release, Nov 20] The seed will be grown mostly in Montana.

Taris Biomedical (Lexington, MA)

Taris Biomedical (Lexington, MA; no SBIR) has raised $15 million, .... based on drug-delivery technologies developed by Cambridge, Mass., scientists.  [Boston Business Journal, Jun 25, 09]

Taris Biomedical (Lexington, MA; no SBIR) announced it has received a $15 million Series A round of venture financing to commence early stage trials of its bladder disease drug device. .... had been operating in stealth mode for about 10 months before emerging at a technology conference Wednesday [Mass High Tech, Jun 25, 09]

Techniscan Medical Systems (SLC, UT)

TechniScan Medical Systems (SLC,UT) got a $2.8M Phase 2 SBIR from NIH to perfect a breast cancer screening tool.  .... Without such support, promising technologies such as the USCT system might not be commercialized, said TechniScan CEO David Robinson.  [Linda Fantin, Salt Lake Tribune, Dec 18]  We hope that NIH had more evidence of market appeal than the company's claims and NIH scientists' hopes. Otherwise, they are just paying for a hobby that will die when the federal dollars end.

Technology and Devices International (Gaithersburg,MD)

Technologies and Devices International (Silver Spring, MD) claimed a revolutionary technical breakthrough by fabricating the industry’s first 6-inch diameter GaN epitaxial materials. 6-inch diameter GaN-on-sapphire epitaxial wafers were fabricated at TDI using it’s patented hydride vapor phase epitaxial (HVPE) process and equipment. TDI has had at least 14 Phase 1s and 3 Phase 2s from MDA. [Nov 04]

Blue Laser Breakthrough. Technology and Devices International (Gaithersburg,MD) made a GaN bulk substrate, which claims to improve the performance and lifetimes of GaN-based device designs. A single crystal GaN sample boule is grown on a GaN seed layer and then sliced into 1.5 inch diameter wafers. TDI's chief executive Vladimir Dmitriev said "The crystals are grown using a 1.5 inch GaN seed crystal and are expected to scale to 3 and 4 inches in the future, TDI has had four Phase 2 SBIRs in the last two years from BMDO and Navy. This substrate advance goes with the BMDO hydride vapor phase epitaxy (HVPE) for multi-layer epitaxial structures for advanced GaN-based devices with quantum wells. But now that BMDO will probably abandon such indirect benefit work, TDI will have to mine ONR harder.

TechTol Imaging (Toledo, OH)

Rocket Ventures, a pre-seed, early-stage venture fund for technology-based [Ohio] companies, has awarded Ignite! grants to three Toledo firms - ADS Biotechnology, TechTol Imaging, and DoX Systems. These grants are given to help the companies develop and use technology to create new products or improve processes that have an impact on jobs and revenues in Northwest Ohio.   [Toledo Free Press, Jun 13, 08]  No SBIR.

TeleContinuity (Germantown, MD)

In May, small companies focusing on security products will have the chance to show off their technologies for the chance to earn investment money and partnerships with a more established firm working with the Department of Homeland Security.  It's part of the American Security Challenge, which encourages universities, entrepreneurs and research labs to demonstrate their technologies. The inaugural challenge held last year awarded $100,000 to a company called TeleContinuity (Germantown, MD; no SBIR) that backs up communication networks in case of a terrorist attack. .... Chart Venture Partners of New York has agreed to pump between $200,000 and $2.5 million into a promising company. And another company will win the chance to team up with Alion Science and Technology, a McLean defense contractor.  ...  submit a summary of their product or company by March 31.  [Kim Hart, Washington Post, Mar 23]

Telik

Telik up 10% [Dec 6, 07]

Telik dropped another 25% after the FDA has placed a clinical hold on the Investigational New Drug (IND) application for TELCYTA® [Jun 6, 07]

Telik dropped 21% after the FDA has placed a clinical hold on the Investigational New Drug (IND) application for TELCYTA® [Jun 4, 07]

Telik up 14% after losing less than expected. [Feb 23, 07]

Telik dropped 71% when a trial became "extremely disappointing". [Dec 26, 06]  Four Phase 1 SBIRs and one Phase 2, including three awards under its original name - Terrapin.

Tengion (East Norriton, PA)

Tepha

Tepha (Cambridge MA; $1M SBIR) got $10.7M private funding. The company licensed its TephaFLEX biopolymer technology, which is based on research conducted at MIT, from its Cambridge neighbor Metabolix Inc. [Mass High Tech, Jun 6]

Terapio

biotech startup Terapio (Austin, TX; no SBIR) plans to announce today that it has raised $5 million to continue developing a line of therapeutic applications. ... founded in 2005, is using research licensed from the University of Texas at Arlington to develop an oral medication that would treat people who are exposed to lethal doses of radiation. [Lori Hawkins. Austin American Statesman, Nov 30, 09]

Two Austin companies will share $3.7 million in grants from the Texas Emerging Technology Fund, which was created to spur commercialization of research in Texas. Receptor Logic Ltd. will receive $2 million to advance its work in the development of anti-bodies that can improve the understanding of the immune system and thus lead to better drugs and vaccines.  Terapio Inc. will receive $1.7 million to develop a cream to treat hand-foot syndrome, a painful swelling and numbness of the hands and feet that can occur as a side effect of several chemotherapy drugs.  Receptor was started in 2004 by Emergent Technologies Inc., an Austin-based life sciences venture capital firm, and Jon Weidanz, director of the Texas Tech University Center for Immunotherapeutic Research. The company, which has headquarters in Austin and a laboratory in Abilene, will use the investment to expand its commercialization efforts  [Lori Hawkins, Austin American-Statesman, Jun 19] Neither had SBIR. 

TeraStor (San Jose, CA)

Frankly, My Dear(Mar 4) Got a hot new technology idea? Get a government grant/contract to develop it in the usual four years of SBIR. Induce Phase 3 investment interest letters to convince government it has commercial potential but cannot raise investment capital for such new and revolutionary technology. Finish development in 2001 and get set for market impact. Sorry, market was preempted by a substitute in 1998. No, government won't tell you about the last line as it blathers about SBIR as a market-driven development program. Alternatively, raise $30M from Paul Allen and friends and unveil a tenfold improvement in disk-drive storage technology, 20GB hard disk, in 14 months from company start-up. "major technical breakthrough" say analysts of TeraStor (San Jose, CA) [Wall Street Journal Mar 3, 1997] . With that, you run Gone With the Wind and/or Hamlet in a window on your PC screen while beavering away writing reports for government contracts.

Templex Technology (Eugene, OR)

Fast Transfer on Fast Track(Aug 28) Templex Technology (Eugene, OR) won a Fast Track Phase 2 SBIR from BMDO for $1M to develop its TASM (Temporally Accessed, Spectral Multiplexing). If it works (if it already worked it wouldn't get a BMDO Phase 2), Templex's president Larry Brice expects a much higher reliability and a quarter lower cost for his terabit per fiber. Technicologically, it's a data storage application to demonstrate a new world's record for density bandwidth product -- 100,000 Terabits per square inch per second. Fast Track gives Templex $1M for $250K third party cash, presumably from the VC on the board. A Fiber Optics News story (Aug 25) quotes Ken Hill, who discovered photosensitivity in optical fiber and invented fiber Bragg gratings as It looks like a clever idea; it remains to be seen how broadly it can be applied. Isn't that always the story with new technology? See the technical stuff in a 39-slide presentation

Deca-Gigabyte Memory.(Jun 11) Tens of gigabytes memory at near semiconductor speed, orders of magnitude more than today's average, at a potential cost of half today's semiconductor memory, says Templex Technology (Eugene, OR) about its Phase 1 BMDO SBIR. (And DRAM is already so cheap that its makers are eating each other's lunch). It's the kind of SBIR that will be either a barn-burner or a burned-barn. If it works, and if it hits the market economics, it could explode into a giant market. It is will not just incrementally advance a someday-useful science (BMDO won't fund that kind of SBIR and neither will the Oregonian VC fund backer).

Tendril

Private companies to watch on electricity as picked by MIT Tech Review (Sep/Oct09): Nanosolar ($1.7M SBIR) founded 2002, raised $400M;  A123 Systems IPO Sep 24; Brightsource Energy; Tendril; 1366 Technologies; Deepwater Wind; Solyndra; Silver Spring Networks; AltaRock; Stirling Energy Systems.

TerraMetrics (Littleton CO)

TerraMetrics (Littleton CO; $1M SBIR since 1999) won an Air Force Phase 1 SBIR for a system to provide a 3D terrain model for helicopter landings in dusty, desert areas with zero visibility, such as Iraq and Afghanistan. [Denver Post, Sep 11]

Tessera Technologies

Tessera Tech down 14% [Jan 7, 10]

Tessera Technologies dropped 6% after the International Trade Commission ruled that three of the semiconductor-packaging technology firm's patents were valid but said the firm didn't prove that rival companies had infringed on two of those patents for dynamic random access memory chips, used in computers and mobile devices. [Wall Street Journal, Dec 31, 09]

Tessera Tech down 18% [Oct 30, 09]

Tessera Technologies may just be the loneliest company in Silicon Valley. Many of the organizations that once flanked Tessera, which specializes in making the tiniest of computing devices, had assembly lines and industrial operations here. They have since withdrawn from ultra-competitive manufacturing, leaving Tessera on its own. In fact, a recent study by the United States Bureau of Labor Statistics shows that Silicon Valley lost more than a quarter of its chip, computer, instrument and communications equipment manufacturing jobs from 2001 to 2008. ....  Tessera’s niche is miniaturization. The company is on a quest to make ladybug-size digital cameras and silent cooling systems, just one-fifth of an inch high, for laptops. ... Many chip makers, including giants like Intel and Samsung, have licensed Tessera’s packaging technology. ... The price of the Tessera devices should go low enough to put a camera into even the cheapest cellphones. [Ashley Vance, NY Times, Aug 16]

A director recently sold $6.7M of Tessera Tech stock. [WSJ, Jun 20, 09]

Tessera up 11% [Jun 3, 09]

Tessera up 11% [May 27, 09]

Tessera up 21% [May 21, 09]

Tessera Tech   up 11% [Feb 3, 09]

Tessera Tech up 12% [Dec 12, 08]

Tessera  down 46% [Dec 2, 08]

Tessera Technologies suffered a setback that rocked its share price when a U.S. International Trade Commission judge said six big chip makers didn't infringe its patents.  ... shares fell 40% in after-hours trading following the news, after closing down 10% in Nasdaq trading  [Wall Street Journal, Dec 2, 08]  On a stock bloodbath day

An arbitration panel found that Tessera Technologies up 30%, [Oct 29,08] has valid patents on certain miniaturization technologies and is owed monetary damages for breaches of a licensing agreement by Amkor Technology.

Tessera Thera down 12% [Oct 15, 08]

Tessera Thera up 18% [Oct 13, 08]

Tessera Tech up 10% [Sep 30, 08]

Tessera Tech down 19% [Sep 29, 08]

Tessera Tech up 14% [Sep 18, 08]

Tessera Tech up 12% [Aug 1, 08]

Tessera up 33%, after the company said the International Trade Commission had overturned a judge's recent decision to stay a patent case against several wireless companies.  [Wall Street Journal, Mar 29]

Tessera Technologies down 18% [Mar 19, 08]

Tessera Technologies up 10%, after saying the status of some of its patents has been mischaracterized [Wall Street Journal, Mar 7,08]

Tessera Technologies fell 39%. The Patent and Trademark Office made a preliminary ruling rejecting claims under a key patent of Tessera, a San Jose, Calif., maker of packaging technologies for chip makers.  [Wall Street Journal, Mar 5]

Tessera Technologies down 34% [Feb 26, 08] The company said a judge decided to stay the company's patent-infringement action before the International Trade Commission pending completion of re-examination proceedings before the U.S. Patent and Trademark Office. [Wall Street Journal, Feb 27]

Tessera Technologies up 11% [Feb 1. 08] after saying it would acquire FotoNation, which provides imaging technologies for digitial cameras and mobile devices. [Reuters, Feb 1]

Tessera Technologies down 15% [Aug 3, 07]

Tetraphase Pharmaceuticals (Watertown, MA)

Tetraphase Pharmaceuticals (Watertown, MA; no SBIR) said it has closed the first tranche of its $25 million Series B financing. ..  launched in 2006 to advance and commercialize the synthetic chemistry platform developed by Andrew Myers of Harvard University.  [Boston Globe, Oct 7, 09]

TetraVue (San Diego, CA)

San Diego’s free high-tech incubator, announced that it has enrolled three more startup companies: TetraVue is developing a high-resolution 3D camera and video recording system; MicroPower Technologies is developing ultra-low-power wireless video surveillance camera technologies;  EcoATM plans to install self-serve kiosks for recycling mobile phones and other consumer electronics.  None has SBIR.

Theragenics (Atlanta, GA)

specialty needle maker NeedleTech Products (Attleboro, MA; no SBIR) has been sold to Theragenics (Atlanta, GA; one Phase 1 SBIR in 1987) medical device company, for $47.8 M cash, according to Theragenics company officials. NeedleTech, a privately held company, develops coaxial needles, biopsy needles, access trocars, brachytherapy needles, guidewire introducer needles, spinal needles, disposable veress needles and other needle-based products. Its products are intended for cardiology, orthopedics, pain management, endoscopy, spine, urology and veterinary markets. [Mass High Tech, Jul 18] Theragenics sells surgical products and trades on the NYSE.

Therametric Technologies (Indianapolis, IN)

Therametric Technologies (Indianapolis, IN; $1.3M SBIR) will launch a new cavity-fighting technology this fall, creating up to 50 jobs. [Indianapolis Star, May 15]

TherionBiologics

Vaccines Can Kill Business. Therion Biologics, a 15-year-old Cambridge company trying to develop a new breed of vaccines to fight cancer, will be shuttered and sold after its most promising drug candidate failed a pivotal human test .. In anticipation of succeeding with at least one of its vaccines, Therion had recently built a manufacturing facility in East Cambridge. [Stephen Heuser, Boston Globe, Jun 29]  Therion had one getting-started HHS SBIR Phase 2 in 1992. From a policy viewpoint, vaccines approach the true market-failure rationale for subsidies like SBIR since they usually have too low a profit potential for Big Pharma but have a huge societal payoff when they work (which is not very often). High risk, low profit, large societal gain.  True market failure should be distinguished from most of the mediocrity that SBIR is used for.

Thermacore (Lancaster, PA)

Modine Manufacturing has completed the sale of its Thermacore division, which makes cooling equipment for electronics, for $13.25 million. The buyer, FSBO Ventures, is owned by current and former members of Thermacore's management. The company based in Lancaster, Pa., has 179 employees, and had $32 million in sales in 2007. Modine acquired Thermacore in 2001. Based in Racine, Modine had $1.7 billion in sales in 2007. [Milwaukee Journal-Sentinel, May 2, 08] Thermacore had $20M SBIR 1984-1995.

Thermage (Hayward, CA)

ThermalTherapeutic Systems (Pittsburgh, PA)

ThermalTherapeutic Systems (Pittsburgh, PA; no SBIR) developer of medical technology, said  it has raised $2.75 million ...  to commercialize ThermalTherapeutics’ technology, which is aimed at the medical community. ... in the final stages of developing a small, portable device to heat and circulate warm, sterile fluids in a number of medical procedures. [Pittsburgh Business Journal, Sep 30, 09]

ThermoCeramiX (Shirley, MA)

ThermoCeramiX (Shirley, MA; no SBIR) which describes itself as the “smart” heating technology firm based in Shirley, has pulled in a $100,000 first tranche of a $2.5 million equity financing round, according to a regulatory filing today. The company develops a spray-on coating designed to heat to temperatures of more than 240 degrees Celsius -- almost instantly.  [Mass High Tech, Sep 14, 09]

Theseus Logic (Orlando, FL formerly St Paul, MN)

ThingMagic, (Cambridge, MA; no SBIR) a radio frequency technology maker, announced its investment and technology development agreement with In-Q-Tel, the CIA’s venture arm.  ... to develop further its RFID reader and sensor technology for industrial, government and consumer applications.  ... Founded in 2000, ThingMagic has brought in more than $30 million in private funding.  [Mass High Tech, Nov 24, 08]

ThingMagic (Cambridge, MA; no SBIR)  closed a $9.5 million round of funding with which the RFID company has raised nearly $30 M since its inception in 2000. .... The 40-person company will use the new financing to expand its product development and penetrate new vertical markets  [Mass High Tech, Jul 11, 08]

Third Wave Technologies (Madison, WI)

Hologic will pay $580 M to acquire Third Wave Technologies (Madison, WI; $9M SBIR) in a deal pairing two developers of medical diagnostics technology. [Boston Globe, Jun 9, 08]

Third Wave Technologies rose 40% in heavy after-hours trading [Mar 11, 08], after the company said a clinical trial for a new test achieved its primary goal.  The test - which Third Wave has been developing for the last two years - is for human papillomavirus, or HPV, a cause of genital infections that might lead to cervical cancer. The company had devoted 80% of its research-and-development budget to creating the test.  [Kathleen Gallagher, Milwaukee Journal-Sentinel, Mar 12]

Third Wave Technologies up 13% [Feb 26, 08]

Third Wave Technologies  reported progress in its efforts to sell products in the biggest potential market it has ever tackled. The Madison maker of genetic analysis products said it has signed up enough people to proceed with clinical trials for its human papillomavirus, or HPV, tests. [Kathleen Gallagher, Milwaukee Journal-Sentinel, Jan 1]

Third Wave Technologies (Madison, WI; $4M SBIR)  got a $25 million, five-year line of credit from Deerfield Management of New York. The money will be used to further Third Wave's business of developing tests for the human papillomavirus. [Milwaukee Journal-Sentinel, Dec 10]

Third Wave Technologies up 11% [Dec 6, 07]

Third Wave Technologies up 25% after winning a patent court case.  [Jul 24, 07]

Third Wave Technologies agreed a private placement of about $14.9 M of debt with an unidentified institutional investor. [Milwaukee Journal-Sentinel, Dec 20]  It has had $4M in SBIR over a decade for its molecular diagnostics. Its stock price sits in the middle of its five-year range.

Thoratech Tech

Medical devices company HeartWare International (no SBIR) reports it is raising approximately $55 million in a private placement of stock with a group of unnamed institutional investors in the United States, and it is considering a similar placement to Australian investors that would raise another $5 million. ... In February, HeartWare announced plans to be acquired by California medical devices company Thoratec  for $282 million. That deal was called off at the end of July, however, after the U.S. Federal Trade Commission said that Thoratec had a monopoly in the left ventricular assist device market and would allow a suit seeking a preliminary injunction to stop the deal, while the FTC looked at the sale more closely.  [Mass High Tech, Aug 11, 09]

Thoratec up 13% [Aug 6, 09]  second-quarter revenue topped Wall Street expectations with help from a heart pump for patients awaiting transplants [Wall Street Journal, Aug 7]

Thoratech up 14% [Dec 5, 08]

Thoratech down 13% [Oct 27, 08]  said there was a wear-and-tear problem with its "HeartMate II" blood-pumping device.  [WSJ, Oct 28, 08]

Thoratech  up 11% [Oct 10, 08]

Thoratech up 22% [Aug 1, 08]

Thorley Industries

Innovation Works, Hazelwood (PA) VC fund, in 2007 invested $6.1 M in technology companies, including its 100th investment.  The  specializes in giving a leg up to young technology companies cites three [no SBIR] success stories: Knopp Neurosciences, which is working on a drug therapy to slow the advance ALS ("Lou Gehrig's disease"). ... granted "orphan drug" status by the FDA ; Printed electronics manufacturer Plextronics, which attracted more than $20 M in new investment last year and set an efficiency record with its solar cells;  Thorley Industries signed a $215 M deal with Hasbro for that company to manufacture and sell a new line of Thorley products  [Elwin Greene, Pittsburgh Post-Gazette, May 2].

Threshold Pharmaceuticals

Rolling Big Dice. Threshold Pharmaceuticals plunged 75% after the Food and Drug Administration halted clinical trials for the Redwood City, Calif., pharmaceutical company's enlarged-prostate drug, TH-070, because of cases of liver toxicity.

Tiax (Cambridge, MA)

Tiax (Cambridge, MA)reports it has granted an exclusive license covering its high-energy, high-performance cathode material to Canadian metal company CVRD Inco Ltd. for use in portable power applications. [MHT, Jul 11]

Tiax (Cambridge, MA; $10M SBIR) has been issued one patent and received one notice of allowance for its Cel-X battery control technology, ...  a low-cost, high-performance system designed to improve the safety, capacity and pack life of lithium-ion batteries through a nondissipative approach to regulating battery charge in lithium-ion batteries, [Mass High-Tech, Jun 21]

Tibbetts Industries (Camden, ME)

 Tibbetts Industries (Camden ME; one SBIR) is being bought by IntriCon , a Minnesota-based developer of miniature and microminiature medical and electronics products, for $4.5M. [Mass High Tech, Apr 20]

Tilera (Santa Clara, CA)

Tilera (Santa Clara, CA; no SBIR) has begun to ship a 64-core processor, promising dramatic advances in powering devices for the networking and multimedia industries. ... "It's a real disruptive technology," [founder MIT professor] Agarwal said last week. "We pretty much took a clean sheet of paper at MIT and said we're going to deliver a whole new architecture for chips." [Robt Weisman, Boston Globe, Aug 20]The technology got tens of millions of dollars from NSF and DARPA and then $40M VC for the company.

TissueLink (now Salient Surgical) (Portsmouth, NH)

Salient Surgical Technologies (Portsmouth, NH; no SBIR, founded as TissueLink in 1999) has landed $15 million in new funding, according to federal documents. The company makes devices to control bleeding during surgeries.  [Mass High Tech, Jan 7, 10]

TLC Precision Wafer (Minneapolis, MN)

If there's a single element of the classic entrepreneur story missing from Tim Childs' seven-year battle to build his small, high-tech company, I've been unable to find it. There were the sacrifices. ... There were the lean times. ... ... And the numbing work schedule. ... Childs, 38, is founder and president of TLC Precision Wafer Technology , a north Minneapolis company that is one of just six firms worldwide capable of supplying gallium arsenide and indium phosphide wafers to the semiconductor industry. ... a steadily growing business that should post sales of nearly $2 million this year, up more than 20 percent from $1.6 million in 1997. The company, which has 18 employees, has been profitable for the past four years ... All of which leaves an intriguing question: How come a poor kid from Miami, the last of eight children in a family headed by a part-time preacher and intermittent mechanic, truck driver and small businessman, wind up with a career in physics? More curious, how does an above-average athlete -- Childs, a linebacker who was defensive captain of his Florida A&M football team -- end up in such an arcane field? "My dad was always giving me thinking problems," Childs said. "He'd say, 'Use your brain, figure things out.' I found that physics gave me the tools to understand how the world around me works. "I just love the science." [Minneapolis Star Tribune, Aug 16] Black jocks do have a life after football. SBIR barely helped with about $1.5M since 1993: 10 Phase 1s and 1 NASA Phase 2.

Tokai Pharmaceuticals (Cambridge, MA)

Tokai Pharmaceuticals (Cambridge, MA; no SBIR) has raised $12 million in an equity finance round, according to official documents. ... founded by Cambridge-based venture capital firm Apple Tree Partners, seeks to in-license and develop endocrine-based drugs to treat diseases such as cancer. Now, according to recent U.S. Securities Exchange & Commission documents, the firm has raised $12 million of a $22 million equity-financing round.  [Mass High Tech, May 8, 09]

TomoTherapy (Madison, WI)

TomoTherapy  up 11% [Nov 16, 09]

Tomo Therapy down 11% [Oct 28, 09]

TomoTherapy  up 12% [Aug 11, 09]

Tomo Therapy up 11% [Jul 31, 09]

Tomo Therapy  down 10% [May 13, 09]

TomoTherapy said  that it is restating its financial statements for 2008 and that its previously reported results should not be relied upon because of errors relating to the accounting for income taxes.  [Milwaukee Journal-Sentinel, Apr 21, 09]

TomoTherapy  reported a net loss on lower sales for 2008 and expects to post a loss on lower or flat sales this year.  [Milwaukee Journal Sentinel, Feb 12, 09]

TomoTherapy   up 10% [Feb 3, 09]

TomoTherapy  down 11% [Jan 27, 09]

Tomo Therapy  up 12% [Jan 23, 09]<

TomoTherapy up 12% [Jan 21, 09]

Tomo Therapy up 15% [Dec 12, 08]

Tomo Therapy down 15% [Dec 11, 08]

Tomo Therapy up 20% [Dec 3, 08]

Tomo Therapy  up 19% [Dec 2, 08]

An investor in TomoTherapy is publicly urging the company's board to actively consider strategic options for the company, even a possible sale, in the wake of the firm's plunging stock price. .. from a high of about $26 in September 2007 to Monday's closing price of $2.56 a share. ... the niche nature of the company's single product and limited installed customer base. Avalon is pushing the board to instead focus on boosting shareholder value via the outright sale of the company, a joint venture or a licensing deal. [Business Journal of Milwaukee, Nov 18, 08]

TomoTherapy up 11% [Oct 30, 08]

TomoTherapy down 11% [Oct 24, 08]

TomoTherapy down 14% [Oct 22, 08]

TomoTherapy up 34% [Oct 20, 08]

TomoTherapy up 14% [Oct 16, 08]

TomoTherapy down 10% [Oct 15, 08]

Tomotherapy down 11% [Oct 8, 08]

Tomotherapy down 11% [Oct 8, 08]

TomoTherapy rose as much as 12% after it said the U.S. Food and Drug Administration approved its TomoDirect technology, a complement to its Hi-Art radiation therapy system.  [Milwaukee Journal-Sentinel, Aug 28]  

TomoTherapy down 49% [Aug 1, 08] after it reported a net loss of $6.9 million in the second quarter, a sharp increase from comparative results a year ago, and said it was removing $53 million in orders from its backlog. [Business Journal of Milwaukee]

TomoTherapy surprised Wall Street by lowering its guidance for results in the first quarter and for the year.  The Madison maker of radiation therapy systems said longer-than-expected timeframes on certain installations and sluggish European sales have it anticipating revenue of $255 million to $290 million and earnings per share in the range of 14 cents to 33 cents for the year.   [Milwaukee Journal-Sentinel, Apr 18, 08]  down 32%

Cashing In. Existing shareholders of TomoTherapy will sell $180M worth of their shares next week which is about 15% above the IPO price. [Milwaukee Journal-Sentinel, Oct 12]

TomoTherapy (Madison WI; one Phase 2 SBIR) shares closed down 8% after it announced plans to sell another 10M shares to the public. [Milwaukee Journal-Sentinel, Sep 22]

Tomotherapy which IPO'd May 9,07 is trading about 20% above the IPO price.

Tomotherapy (Middleton WI; one Phase 2 SBIR) might raise as much as $200 million for the 10-year-old maker of what some have called a revolutionary system for delivering radiation to cancer patients ... had nearly 500 employees in December, and it expects to report $50 million to $52 million of revenue for the first quarter, [Kathleen Gallagher, Milwaukee Journal-Sentinel, May 7]

TomoTherapy(Madison WI, one Phase 2 SBIR) filed to go public to raise $200M. It makes a highly precise system (sub-millimeter accuracy) for treating cancer with radiation [Rick Rommel, Milwaukee Journal-Sentinel, Feb 13]

TranS1 (Wilmington NC)

TranS1 (Wilmington NC; no SBIR) did an $82M IPO after which the shares jumped 60%. ... focused on developing innovative, minimally invasive surgical procedures for treatment of low back pain (LBP). [company website]

TransEnterix (Durham, NC)

TransEnterix (Durham, NC; no SBIR) is poised to begin selling its first products after obtaining all of the necessary regulatory approvals for its new surgical system and finding new space to assemble them. ... leased 37,000 square feet of space in Morrisville's Keystone Technology Park ... founded in 2006, is being fueled by the $55 million it raised in October [David Ranii, Raleigh News & Observer, Jan 19, 10]

Medical device maker TransEnterix (Durham, NC; no SBIR) landed $55M in a second round of venture-capital funding ... to bring its surgery technology to market next quarter and hire some 50 new employees over the next 14 months. [Triangle Business Journal, Oct 7, 09]

 A young, fast-growing medical device company has raised $55 million in venture-capital financing,  TransEnterix (Durham, NC; no SBIR) will use the money to manufacture and market a device that promises scar-free abdominal surgery to repair hernias or remove gall bladders, ovaries and appendixes.  [Raleigh News & Observer, Oct 8, 09]

TransEnterix (Durham, NC; no SBIR) raised $21M in VC to chase every surgeon's dream: to cure without cutting.... is a brain child of Synecor, a business incubator that spun out of Duke University seven years ago to turn medical device ideas into money makers. [Sabine Vollmer, Raleigh News&Observer, Jan 8, 08]

TransMedics (Andover, MA)

TransMedics (Andover, MA; no SBIR) medical device firm, has raised $2.5 million in a debt offering ...  launched in 1998 to provide more effective organ transplant support technologies .... Last December, pulled its [$86M IPO] registration ... has raised more than $90 million in venture capital from 10 different firms   [Mass High Tech, Jul 16, 09]

TransMedics (Andover, MA; no SBIR),  a medical device company that filed plans to go public in September 2007, has yanked its initial public offering, citing unfavorable market conditions ... So far, there have been 43 IPOs priced this year - including just one since the end of August - compared with 272 last year, according to Renaissance Capital's IPOhome.com. [Todd Wallack, Boston  Globe, Dec 17, 08]

Transmeta (Santa Clara, CA)

Transmeta up 19% [Sep 25, 08] as the maker of software-based microprocessors reached new licensing deals with computer-chip and microprocessor manufacturer Intel. [Wall Street Journal]

Transmeta reviewed a range of strategic options over the past few months and concluded that finding a buyer was the best thing for shareholders, according to a statement today. Separately, Transmeta said it signed agreements to license its patents to Intel for $91.5 million, speeding up payments from an earlier deal. ... once backed by billionaires George Soros and Paul Allen, set out originally to make low-power computer processors chips in competition with Intel, the world's largest semiconductor maker. After failing to win enough market share, the company focused on just licensing its chip designs.  [San Jose Mercury News, Sep 24]

Transmeta gained, however. The shares jumped 9.75 to 13.93 after the computer-chip developer struck a licensing deal with Intel, settling all outstanding patent disputes.  [WSJ, Oct 25]

Transmeta (Santa Clara, CA; no SBIR (too secret)) fell 18% after the semiconductor company launched a plan for a $12.8 M follow-on share and warrants offering.  [Wall Street Journal, Sep 22]

TransMolecular (Cambridge, MA)

TransMolecular (Cambridge, MA; $1M SBIR) said that the FDA has granted orphan drug designation for a drug candidate that aims to treat Stage IIb-IV melanoma, the deadliest form of skin cancer.  [Chris Reidy, Boston Globe, Dec 23, 08]  Founded in 1996 on technology originating from the University of Alabama at Birmingham and currently located in Cambridge, MA, TransMolecular is privately held and funded by venture capital, raising $42.8M to date through three private placements [company website]

The FDA granted TransMolecular (Cambridge, MA, originally Birmingham AL; $1M SBIR) its "orphan drug" designation for the non-radiolabeled version of TransMolecular's anti-cancer compound TM601, which is entering clinical trials for the treatment of the brain cancer known as malignant glioma, company officials say.  [Mass High Tech, Jan 7, 08]

For 11 years, TransMolecular (Cambridge, MA; $1M SBIR in Alabama) has been working on a promising brain cancer treatment from a substance found in scorpion venom.  ... already raised $43 M VC, hopes to raise additional funding as it embarks on pivotal clinical trials. ... one of about three dozen local biotech companies slated to speak at the Massachusetts Biotechnology Council's annual investor conference in Boston ... And ready money is available: According to Ernst & Young, the US biotech industry raised $14B in financing through the first half of the year, putting it on pace to beat the 2006 total by 40%. [Todd Wallack, Boston Globe, Nov 5]

TransTech Pharma (High Point, NC)

Jobs. A clinical-stage pharmaceutical company and its spinoff company will invest $23M in High Point with plans to create 205 jobs within five years. The majority of the jobs will come from TransTech Pharma (High Point, NC; $1.4M SBIR), and PharmaCore will bring about 50 positions. If TransTech creates all its jobs and sustains them for 12 years, it could receive up to $6.57 M in benefits under the state Job Development Investment Grants program. [Raleigh News&Observer, Dec 21]

Transzyme Pharma (Durham NC)

Three deep-pocketed investors are betting $20M on Transzyme Pharma (Durham NC; no SBIR; 44 employees) that is working on treatments for serious constipation. It's the trio's second large investment in Transzyme in three years. ... targeting gastrointestinal treatments was a calculated decision, Garg said. Few competitors exist for innovative gastrointestinal medicines. [Raleigh News&Observer, Nov 1]

TrellisBioscience (South San Francisco CA)

Trellis Bioscience (South San Francisco CA, $0.5M SBIR) that monitors cells at the individual level to assess what sort of treatments to give people, said it has raised $10M in a second round of financing. ...  Novartis Bioventures led the round [Venture Beat, Feb 14]

Trex Enterprises (San Diego CA)

Efficient Ears. On average, companies generated roughly $28 in earmark revenue for every dollar they spent lobbying. By any standard, that's a hefty ratio: The companies in the Standard & Poor's 500-stock index brought in just $17.52 in revenues for every dollar of capital expenditure in 2006. ... Says Keith Ashdown, chief investigator for the watchdog group Taxpayers for Common Sense: "The lion's share of these projects is about politics and jobs, rather than real needs." [Business Week, Sep 17]  The earmark efficiency champ is an SBIR company, Scientific Research (Atlanta GA and others; about $15M SBIR), that got $344 in earmarked funds per dollar of political "investment".Other SBIR investors: Isothermal Systems (KY and WA; $2M SBIR) at $221 per lobbying dollar; Prologic (Fairmont WV; $2M SBIR) at $133 per dollar; Trex Enterprises (San Diego CA; $7M SBIR) at $116 per dollar. From an efficiency viewpoint, politicians make a good investment. You just have to learn how to kiss frogs.

Trident Systems

On May 10, 2006, Team Submarine (Team Sub) awarded Trident Systems a contract worth $50M for the delivery of Shipboard Mobile Computing Engineering Model under the SBIR program. This award represents the billionth dollar that Team Sub has awarded under the SBIR program, in Phase IIIs alone, since it began more than a decade ago. Says the Navy's Summer 2006 Transitions, now on the Navy SBIR website.  Trident knows how to play the game with at least 109 Phase 1s since 1989 and 33 Phase 2s, several over $1M. The Navy SBIR puts great weight on the companies' connecting with and serving Navy programs.  How much is innovation and how much is plain vanilla R&D service is left for the Navy programs to decide.  Which seems to work just fine for the goal of spending SBIR on things the Navy wants while the Navy sees no other worthwhile goals for its SBIR.

Trimeris  (Morrisville NC)

Trimeris down 17% [Dec 29, 09] after South Korean medical equipment maker Arigene ended its $80.3 million acquisition offer for the Durham, N.C., biopharmaceutical maker because it was unable to secure sufficient financing. [Wall Street Journal, Dec 30]

Trimeris down 18% [Nov 12, 09] The proposed $81 million acquisition of AIDS drug company Trimeris is in jeopardy. The Durham-based company announced that the South Korean company that wants to buy it has asked for more time because it currently lacks the money and financing to complete the deal  [David Ranii, Raleigh News & Observer, Nov 12, 09]

Trimeris up 37% [Oct 2, 09]

Trimeris, a once-promising biotech company that failed to reach its potential, is being acquired by a South Korean medical equipment company.  [Raleigh News & Observer, Oct 3, 09]

For the first time since Trimeris won approval to sell Fuzeon in spring 2003, annual global sales of the HIV/AIDS drug decreased.  ... Demand for Fuzeon has waned since powerful new AIDS drugs started coming to market in 2007 ... has closed its research lab in Morrisville [Sabine Vollmer, Raleigh News & Observer, Feb 4, 09]

Trimeris  up 15% [Dec 10, 08]

Trimeris up 12% [Oct 23, 08]

Trimeris down 12% [Oct 3, 08]

Trimeris down 12% [Oct 3, 08]

Trimeris up 16% [Sep 18, 08]

Trimeris  down 13% [Sep 17, 08]

Trimeris down 12% [Jun 23, 08]

The quarterly earnings report Thursday from Trimeris -- once among the Triangle's most promising biotechnology companies -- could be one of its last.  After laying off all but 10 employees, winding down research and development and putting the company's Morrisville laboratory up for lease, the money managers and investment firms that make up Trimeris' board have decided to begin disbursing one of the company's remaining assets -- $80 million in cash and cash equivalents. .... At its peak, Trimeris employed about 150 people, before Fuzeon failed to meet expectations  [Raleigh News & Observer, May 9, 08]

Too Much Competition. Trimeris down after reporting that first-quarter sales of its Fuzeon AIDS drug dropped 34%. ... Other drugs to treat HIV and AIDS have eclipsed Fuzeon, including new products from Pfizer and Merck that became available last year. ... The stock began trading publicly in 1997 and soared above $70 in 2000, largely on the potential of the company's revolutionary medicine to treat AIDS. But patients and physicians balked at the drug's high cost and painful daily injections. ... down from 150 workers to 10   [Alan Wolf, Raleigh News & Observer, Apr 18, 08]

After being loved and left several times in the past decade, a sizable Morrisville (NC) building is on the rebound, in search of someone who will appreciate it for what it is on the inside: a lab. Trimeris, a once-promising drug developer, is trying to sub-sublease its 61,000-square-foot research facility  ...  The Triangle is teeming with hungry lab hunters at a time when other sectors are expanding cautiously, if at all.  [Jack Hagel, Raleigh News & Observer, Apr 14]

Dani Bolognesi will take another run at developing a novel, blockbuster drug, an accomplishment that eluded him when he led Trimeris. As chief executive and chairman of B3Bio, a startup, Bolognesi is looking for a new class of medicines that promises to better treat cancer, inflammation and infection. At Trimeris, a troubled Morrisville drug development company, Bolognesi had a similar goal with AIDS drug Fuzeon. [Sabine Vollmer, Raleigh News&Observer, Mar 12, 08]

Price Too Dear. AIDS drug company Trimeris (Morrisville NC) plans to halt its research and development efforts and lay off its R&D staffers next year. The new strategy announced after the markets closed Monday follows last month's appointment of a new CEO -- the company's fourth chief executive in the past year -- and a steady stream of turmoil. ...Trimeris' AIDS drug Fuzeon has racked up disappointing sales, partially as a result of its steep price tag of about $20,000 a year [David Ranii, Raleigh News&Observer, Dec 11]

Trimeris generated third-quarter earnings that trounced analysts' estimates. The company mostly credited higher overseas sales of its HIV/AIDS drug Fuzeon for a 61%earnings increase from the same period a year ago. [Raleigh News&Observer, Nov 9, 07]

The short-time CEO and CFO at Trimeris are departing as allegedly planned after they did their six-month job of creating a blueprint for developing a new AIDS drug, TRI-1144. Meanwhile,  HealthCor -- now the company's largest shareholder with a stake of nearly 18% -- has urged the company to halt development of a new drug and consider putting itself up for sale. [Raleigh News&Observer, Oct 12]

Trimeris and its Swiss partner Roche said that they will withdraw an application to sell HIV/AIDS drug Fuzeon in a needle-free device. ...the FDA, concerned that the device could cause nerve pain and bruising, delayed approval and asked for additional data.  [Raleigh News& Observer, Oct 4]

Over the past two months, a New York investment firm has bought more than 9 percent of Trimeris shares, filings with the Securities and Exchange Commission show. HealthCor Management, which has more than $1.8 billion under management, isn't saying what it plans to do with its stake in the struggling Morrisville drug company.  Trimeris executives aren't returning calls. [Raleigh News & Observer, Aug 10]

 CEO by the Hour. Two top executive positions [filled by outside consultants] at Trimeris, the struggling Morrisville NC company that specializes in AIDS treatments, will be paid on an hourly basis for as long as another 16 months ... Company officials did not return phone calls, and an analyst who follows Trimeris said it isn't clear what strategy the firm is trying to pursue. [Raleigh News & Observer, Aug 8, 07]

Trimeris up 11%  [Aug 8, 07]

Less Acceleration. Trimeris, the troubled Durham company that markets the AIDS treatment Fuzeon with its Swiss partner Roche, reported that worldwide sales increases for Fuzeon slowed in the first quarter. [Raleigh News & Observer, Apr 18] Trees don't grow to the sky.

Trimeris up 15% on hot quarter revenue. [Apr 18, 07]

Trimeris plunged 29% on the the resignation of CEO/CSO and CFO and termination of an R&D deal with Roche. [Mar 16, 07]

Trimeris up 20% on news of reshuffling of emphasis and some people. [Nov 15, 06] 

Trimeris shot up 23% on news of greatly improved profits fueled by the growth in sale of its HIV drug Fuzeon [Nov 8, 06]

Trimeris shares dove 13% after the company lowered sales projections for its AIDS drug Fuzeon. Even so, it expects to post yearly profit for the first time since beginning operations 13 years ago. [David Ranii, Raleigh News and Observer, Oct 12] Trimeris had one Phase 2 SBIR in 1997.

Triquint Semiconductor

TriQuint Semiconductor said it has been awarded a $16.2 million [DARPA] contract to conduct advanced semiconductor research. [Portland Business Journal, Oct 23, 09]

TriQuint Semiconductor down 28% [Oct 22, 09] third-quarter revenue fell below estimates and it said a key customer was cutting orders. [AP]

Triquint up 10% [Jul 23, 09]

TriQuint down 10% [Jun 16, 09]

TriQuint up 17% [Jun 1, 09]

Triquint   up 10% [Apr 23, 09]

Triquint  up 12% [Apr 6, 09]

Triquint   up 11% [Feb 6, 09]

Triquint down 14% [Jan 7, 09]

Triquint up 10% [Jan 5, 09]

TriQuint up 18% [Dec 30, 08]

TriQuint up 18% [Dec 17, 08]

TriQuint up 12% [Dec 8, 08]

TriQuint  down 11% [Dec 1, 08]  On a stock bloodbath day

Triquint down 10% [Nov 6, 08]

Triquint up 14% [Oct 28, 08]

Triquint up 11% [Oct 16, 08]

Triquint down 14% [Oct 15, 08]

Triquint up 11% [Oct 13, 08]

TriQuint down 18% [Oct 7, 08]

TriQuint down 18% [Oct 7, 08]

TriQuint up 11% [Feb 25, 08]

Triquint up 11% [Oct 31, 07]

Triquint Semiconductor up 15% [Oct 25, 07] after the company reported a 19 percent jump in third-quarter revenue

Triton Systems (Chelmsford, MA)

Triton Systems (Chelmsford, MA) got Israeli VC financing to spin off three new companies, Elecon, Sensera, and Tribond. Elecon will sell TOR-CPä conductive polymers for the electronics marketplace. Sensera will sell electronic sensors to monitor and detect chemical and bio-contamination in fluids with Triton’s conductive polymer film technology. TriBond will sell Smart-Bond, a temperature-controlled welding/sealing technology using radio frequency (RF) energy. Privately-owned Triton Systems claims to have grown 45% annually since its founding in 1992 by Ross Haighihat who left SBIR-champ Foster-Miller.

Triton Systems (Chelmsford, MA) ... is a "creative explosion." The materials product and process development firm recently launched three new spin-off companies and met with members of the Senate Small Business Committee last week to present its new products. ... the gurgling test tubes and grunting machines are churning out polymers. Triton specializes in using nanotechnology methods to create lightweight, durable plastic products for the military, aerospace and commercial industries. Its NanoTuf protective polymer coatings are used on military visors and windshields, and its materials have been used for everything from automotive parts to space suits. The company creates military food trays that can withstand a fall from a helicopter, and its durable plastic capsules are used to hold helium on Converse's line of helium running shoes. Triton also produces an award-winning space-shielding material that enables spacecrafts to survive up to 10 times longer in orbit. .. SBIR has been one of Triton's primary financial supporters since the company was founded in 1992. ... Chief Operating Officer David Model said most ideas take many years to develop into products. Some work, and some don't, he said. "But you just keep trying." Triton is also working on four other potential spinoffs currently in incubation. The company has seen 45% annual growth, Model said, and he anticipates revenues in the area of $8M this year. Triton started with three staff members and currently employs more than 50, with plans to hire 20 more by year's end. The plan is to continue to expand Triton's commercial products and eventually go public, Model said. "Our goal is to no longer need SBIR," he said. [Peter Key, Staff Writer, Lowell Sun]. Triton was founded by a former SBIR user at Foster-Miller, the going-away SBIR champ at gathering funds.

More is Less. A venture between Israeli investment group KPP Investments and Triton Systems (Chelmsford MA; 181 Phase 1s and $55M Phase 2 SBIR) has yielded a new company, FRX Polymers LLC in Chelmsford, is expected to work to commercialize a new family of flame retardant polyphosphonate homopolymers and copolymers. [Mass High Tech, Sep 28] Great fire, but after how much government kerosene? When should the government say enough, or at least keep raising the barrier to new projects? A progressive barrier makes the company reach farther for either highly disruptive new technology or for proof of market validation of the company's technical successes. Well, as long as the agencies are forced to divert a noticeable percentage of their R&D budgets into political programs, the more pressure they feel to take it back in the form of contracts to do what they would have done if the money had not been sequestered. When SBIR was only 1.25% of extramural spending, it could focus on truly inventive stuff. Raising it to 2.5% and then plumping for even more forced it into the same mold as all other R&D programs in the mission agencies. Triton Systems (Chelmsford, MA) acquired Israel-based Ceramight for an undisclosed amount, and has combined it with its extreme environmental composites group to form a new subsidiary called Ceracom Inc. [Mass High Tech, Apr 2]

Triton Systems is selling a nanoengineered plastic pouch for use as a helium-filled heel cushion in Converse Helium sneakers sold in Japan and China. Trition uses an additive of clay nanoparticles to tighten the molecular structure of the pouch, allowing it to trap the helium underfoot for a minimum of 18 months, said Ross Haghighat, Triton's CEO. [Boston Globe, Sep 10]

Trubion Pharmaceuticals

Trubion Pharma  up 20% [Jan 25, 10] led all NASDAQ risers

Trubion Pharma up 10% [Dec 14, 09]

Trubion Pharma down 10% [Sep 2, 09] 

Trubion Pharma up 13% [Aug 31, 09] 

Trubion Pharma up 45% [Aug 28, 09]  Facet Biotech Corp. will pay Trubion Pharmaceuticals Inc. as much as $196.5 million and make a $10 million investment in the company in return for the marketing rights for an experimental leukemia drug, the companies said [AP, Aug 28]

Trubion Pharma up 30% [Jul 27, 09]  drug giant Wyeth is extending its collaboration with Trubion for an additional year, through December 2010 [Puget Sound Business Journal, Jul 27]

Trubion Pharma up 11% [May 29, 09]

Trubion down 19% [May 21, 09]

Trubion Pharma   up 18% [May 18, 09]

Trubion Pharma  up 31% [May 15, 09]

Trubion Pharma down 16% [Oct 8, 08]

Trubion Pharma down 16% [Oct 8, 08]

Trubion Pharmaceuticals said that it’s won a preliminary patent skirmish in Europe.  .... the Opposition Division of the European Patent Office has revoked a Genentech Inc. and Biogen Idec Inc. patent for a rheumatoid arthritis treatment antibody.  [Puget Sound Business Journal, Sep 11]

Trubion Pharma  up 13% [Sep 18, 08]

Trubion Pharma down 14% [Sep 8, 08]

Trubion Pharma up 11% [Sep 5, 08]

Trubion Pharma up 15% [Jul 11,08]

Trubion Pharma down 10% [Jun 23, 08]

Trubion Pharmaceuticals up 13% said that Wyeth has exercised its option under the terms of its collaboration agreement with Trubion to extend the research period for an additional one-year period. [press release, Jun 19, 08]

Trubion Pharmaceuticals  down 14% [Jun 6, 08]

Trubion Pharmaceuticals  up 10% [May 27, 08]

Trubion Pharmaceuticals down 20% [Apr 22, 08] after it launched a new clinical trial of a rheumatoid arthritis drug with partner Wyeth

Trubion Pharmaceuticals up 13% [Apr 18, 08]

Trubion Pharma up 12% [Apr 16, 08]

Trubion Pharmaceuticals up 14% [Apr 10, 08]

Trubion Pharmaceuticals up 10% [Mar 31, 08] after a downgrade recommendation.

Trubion Pharmaceuticals down 15% [Mar 28, 08] and down 47% over 52 weeks.

Trubion Pharmaceuticals up 22% [Mar 20, 08]

Trubion Pharmaceuticals down 19% [Mar 17, 08]

Trubion up 22% [Mar 11, 08]

Trubion Pharmaceuticals  down 10% [Feb 14, 08]

Trubion Pharmaceuticals up 15% [Feb 13, 08]

Trubion Pharmaceuticals up 10% [Feb 6, 08]

Trubion Pharmaceuticals down 12% [Feb 5, 08]

Trubion Pharmaceuticals up 13% [Jan 25, 08]

Trubion Pharmaceuticals (one SBIR) up 20% [Jul 25, 07] and 54% for 52 weeks.

Tryton Medical (Newton, MA)

Tryton Medical (Newton, MA; no SBIR, founded 2003), a developer of coronary stents, reports it has raised $14 Min a Series C VC round. [Mass High Tech, Apr 1, 08]

TVA Medical (Austin, TX)

TVA Medical (Austin, TX, founded 2008) has raised $2.6 million to continue developing minimally invasive therapies for renal disease. [Lori Hawkins, Austin American Statesman, Jan 10, 10]

UCAN (Woodbridge, CT)

Apparently spun out of a biotechnology company, startup UCAN (formerly GlyGenix Woodbridge, CT; no SBIR) landed $624,000 of a planned $2.5 million funding round ... focused on marketing a nutritional sports product it calls SuperStarch ... GlyGenix, however is focused on treating and curing Glycogen Storage Disease Type 1a ... GlyGenix took a $1.645 million Series A round of funding in January  [Mass High Tech, Dec 28, 09]

UES (Beavercreek, OH)

Helping the Neighbor. Beavercreek-based UES (once called Universal Energy Systems (Dayton);  Beavercreek, OH; about $40+M SBIR) was awarded a $22.7 million [USAF-AFRL] contract [for] research, development and technology transition on advanced metallic and ceramic structure materials. In September, UES snagged a six-year, $44.5 million deal to provide research and development for the nano and biological materials. [Dayton Business Journal, Dec 31, 09] in 2009, it was still getting Phase 1 SBIR awards, its 140th Phase 1 following about 40 Phase 2s.  DOD's due diligence on SBIR must not include a check on whether a firm is ready to compete for mainline DOD R&R funding and thus does not need nursery funding.  Did the Congress intend such situations in SBIR?  Well, the Dayton Congressional delegation will certainly not be complaining about a firm parked outside the DOD gate getting a lot of contracts. What are neighbors for anyway? I do hope that the big contracts do not include consulting work on SBIR topics and selection of winners.

UltraCell

Army's venture venture.  The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs;  Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries;  Integrated Fuel Cell Technologies  (Burlington MA; no SBIR) next generation fuel cell systems for portable devices;  Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates,   PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets;  Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell.  [defense-ventures.com]  No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

UltraCell  (Livermore, CA; $800K SBIR) will get $1 million from the state of Ohio to help move more of its manufacturing operations to the Dayton region. .. has production operations in the area, recently landed a $3 million contract [funded by stimulus dollars] with the USAF to develop portable fuel cells for use by soldiers in the field.  ...  raised $3.8 million in venture funding to help expand operations at its facility in Dayton. ... has raised $30 million total since it was started in 2002 [Dayton Business Journal, Dec 18, 09] launched with technology licensed from Lawrence Livermore National Laboratories ...  [In 2007] it planned to invest $74M in the Dayton operation. The state has promised $15.2M in loans, grants and tax credits.  [Dayton Business Journal, May 15, 07]  portfolio.com lists James Kaschmitter as Chairman & CEO. Kaschmitter had a battery firm Polystor ($500K SBIR in 1996) and founded PowerStor (no SBIR) in 1997 as a spin-off from PolyStor [allbusiness.com, Dec 99].

Fuel cell maker UltraCell (Livermore, CA; $800K SBIR) raised $3.8 million in venture funding to help expand operations at its facility in Dayton OH, where it has added a handful of workers since December. [Dayton Business Journal, May 26, 09]

UltraCell (Livermore, CA; no SBIR) has developed a 25 watt fuel cell that can power the military's rugged laptops for up to eight hours on eight-and-a-half ounces of methanol. Intrigued, DARPA and the Army CERDEC have granted UltraCell a follow-on contract to refine their fuel cell tech for laptop-toting soldiers in the field. [Matt Safford, Extreme Tech, Jun 24, 08]  Note that it needs an ounce of methanol per hour which has to be transported from Kuwait to the forward bases and somehow mated with the power supply.

Kaschmitter Still in Power. Energy source isn't powering cars as expected, but startups, others making progress on smaller scale. UltraCell Corp (no SBIR) plans to open its plant this week ... near Dayton OH. ... CEO Jim Kaschmitter was a researcher at the Department of Energy's Lawrence Livermore National Laboratories in California before he started UltraCell in 2002. [Austin American-Statesman, Sep 9, 07] In between, he was also CEO and President at PowerStor and PolyStor Corporations.  PolyStor (Dublin, CA; one Phase 2 SBIR) was to become the first American manufacturer to mass produce rechargeable lithium-ion batteries, powering millions of wireless phones and laptop computers.... PolyStor has spun off a second company, PowerStor (no SBIR), that will focus on super capacitors that can quickly discharge far more energy than those now on the market. PolyStor has also signed a $9.5 million contract to develop and deliver batteries for hybrid electric cars, which will run on a combination of battery power and gasoline. And bicycles may be next.  [East Bay Business Times, Nov 1998]  The Commerce ATP Program reports that PowerStor licensed aerogel capacitor technology from Lawrence Livermore National Laboratory. PowerStor overcame financial barriers to constructing production facilities by manufacturing its aerogel ultracapacitor products by hand in Malaysia.  Cooper Electronic Technologies acquired PowerStor when the parent company, PolyStor, folded [Missile Defense Agency 2003 Technology Applications Report: Electrical, Electronic, and Magnetic Devices] (Note: Unlike the other SBIR programs, MDA's Tech App program keeps up with company developments that come from its SBIR investments.) and that In 2000, PolyStor won an award from the Advanced Technology Program to help develop a safe, ultrahigh capacity next-generation rechargeable battery based on Li-ion polymer gel technology. After suffering a sharp decline in demand for its products in 2001, tied to a global decline in the demand for cell phones, PolyStor ceased operations in 2002. [Source: Steve Peng. "Mold to Fit Battery." Edgereview]

Ultralife (born Ultralife Batteries)

Ultralife up 10% [Dec 22, 09]

Ultralife down 13% [Oct 21, 09]

Ultralife  down 13% [Oct 20, 09]

Ultralife down 11% [Sep 28, 09]

Ultralife up 10% [Jun 29, 09]

Ultralife  down 16% [Apr 30, 09]  reported Thursday a drop in revenues and a first-quarter net loss Thursday, driven by lower shipments of some products and an increase in operating costs. [Andrea Deckert, Rochester Business Journal, Apr 30, 09]

Ultralife  up 10%% [Mar 31, 09]

Ultralife  up 10% [Mar 23, 09]

Ultralife down 11% [Mar 20, 09]

Ultralife up 12% [Mar 10, 09]

Ultralife down 13% [Jan 22, 09]

Ultralife up 13% [Dec 5, 08]

Ultralife  down 18% [Dec 1, 08]  On a stock bloodbath day

Ultralife up 15% [Nov 26, 08]

Ultralife up 23% [Nov 21, 08]

Ultralife up 11% [Nov 13, 08]

Ultralife up 13% [Nov 7, 08]

Ultralife down 10% [Nov 5, 08]

Ultralife up 19% [Oct 28, 08]

Ultralife up 12% [Oct 16, 08]

Ultralife down 11% [Oct 15, 08]

Ultralife down 10% [Oct 7, 08]

Ultralife down 12% [Oct 2, 08]

Ultralife down 10% [Oct 7, 08]

Ultralife down 12% [Oct 2, 08]

Ultralife down 19% [Sep 29, 08]

Ultralife up 13% [Sep 18, 08]

A boosted outlook helped shares of Ultralife Batteries, which gained 31%. ... raised its second-quarter and full-year revenue forecasts [Wall Street Journal, May 30]

Ultralife up 16% [May 1, 08]

Ultralife down 15% [Mar 28, 08]

Ultralife up 13% [Mar 27, 08]

Ultralife down 17% [Feb 15, 08]

Ultralife down 14% [Jan 30, 08]

Ultralife down 17% [Jan 11, 08]

Ultralife Batteries (Newark, NY) up 17% on a $40M order [Dec 26, 07] after it said that revenue will soar to a record high next year.

Ultralife Batteries up 12% [Sep 27, 07]

Ultralife Batteries dipped 12% on a dipping forecast of a quarterly loss. [Oct 26. 06]

Ultramet (Pacoima, CA)

Ultramet Wins Again(Sep19) Ultramet (Pacoima, CA) won $175K develop a spin-off application for cutting-edge coatings for the drilling industry. The money comes from the Los Angeles Regional Technology Alliance to help companies compete for federal funding (love that interstate competition). Help? Hah! Ultramet should have been on the selection committee. Ultramet's $15M puts it in the top twenty SBIR winners - the premier federal money for start-up companies. This time Ultramet got a nudge from BMDO, one of Ultramet's generous suppliers of SBIR funds, in the form of a nomination to LARTA through an experiment by BMDO's Technology Applications program (one of the government's best) with the National Association of State Development Agencies (NASDA). While BMDO's motive was to help its SBIR companies succeed in real life (and get off the federal handout), I wonder if BMDO knew what reinforcement of dependency it was risking. The similar grant to Aguila (San Marcos, CA), in San Diego's competition, makes a lot more sense if the objective is to give the fledgling most-likely-to-succeed California companies a one-time hand in the federal competition. Ah well, I suppose I have to share LARTA's blame since I gave Ultramet a lot of that SBIR money over the last decade. None of the other winners is an SBIR junkie (uh, veteran).

UNIAX (Santa Barbara, CA)

Konarka Technologies launched a new $45 million R&D deal with Total Gas & Power Ltd., a UK-based oil and gas company.  With the deal, Total will become the leading stakeholder in Konarka, with a slightly less than 20 percent share. ... Konarka’s thin-film technology allows for the colored printing and application of a polymer material that can convert light into energy. The technology, originally developed by the late Sukant Tripathy, a materials scientist and professor at the University of Massachusetts Lowell, and Alan Heeger, a 2000 Nobel Laureate in Chemistry, has attracted a lot of attention since the company was founded in 2001, as well as more than $100 million in private funding from a number of investors. [Mass High Tech, Dec 15]  Heeger did the chemistry of conductive plastics that became the bedrock of UNIAX that Heeger co-founded and got SBIR from BMDO in 1992.

Nobel Prize touches SBIR company(Oct 11) One of the Nobel laureates in chemistry was Alan Heeger, of the University of California-Santa Barbara, who did the chemistry of conductive plastics that became the bedrock of UNIAX that Heeger co-founded. Its first Phase 2 SBIR came from - you guessed it - BMDO in 1992.

Uniax bought.(Apr 24) DuPont bought UNIAX (Santa Barbara, CA) for the world’s first polymer-OLED (organic light-emitting diode) displays. Poly-OLEDs are critical to developing brighter, lower cost and lightweight displays for use in wireless devices, such as cell phones and personal digital assistants. Price unnamed. Dr. Nick Colaneri, Director of New Technology at UNIAX said, A complete OLED display is less than 2 mm thick and weighs about 1/10 oz. Current display prototypes have in excess of 25,000 pixels, suitable for wireless Internet applications. The displays are daylight readable, and capable of displaying full motion video. UNIAX Corporation started in 1990 with conducting polymer technology developed by Dr. Alan Heeger and licensed from the UCSB. UNIAX got its start as an SBIR Phase 2 from (who else?) BMDO in 1992 and has had seven Phase 2s, three from BMDO. No more SBIR, now, of course, for a subsidiary of a 94000-employee company. UNIAX got its start as a Phase 2 recipient of (who else?) BMDO.

Lighted SiliconPaint a few lines on the silicon surface and overcoat them with the magic polymer, activate the circuit in the silicon with less than 4V and Voila - The Polymer Shines. Not just any polymer though. UNIAX Corp (Santa Barbara, CA) owns the right shiny polymer with which it reported the Light Emitting Electrochemical Cell in Science 1995 after its 1994 Phase 1 BMDO SBIR. UNIAX sees this set-up pushing aside two presently pursued technologies: light emitting epitaxial layers like AlGaAs/GaAs, and porous silicon. (When will these technology advances stop obsoleting DOD's investments? Can't we halt the sledgehammer of progress and return to an orderly world?) Since then it has attracted well over $1M beyond the SBIR subsidy plus one large chemical company is putting in a new $1M. The professor-started company has now got a business type CEO, Jim Long, a sine qua non for business success.

Unica

Unica up 10% [Jul 15, 09]

Unica  down 12% [Mar 27, 09]

Unica  up 19% [Mar 23, 09]

Unica up 17% [Mar 10, 09]

Unica  up 10% [Mar 6, 09]

Unica  down 11% [Mar 5, 09]

Unica up 11% [Mar 4, 09]

Unica down 12% [Mar 2, 09]

Unica up 11% [Feb 26, 09]

Unica  up 16% [Feb 24, 09]

Unica down 11% [Jan 9, 09]

Unica up 13% [Dec 31, 08]

Unica up 25% [Dec 16, 08]

Unica up 20% [Dec 8, 08]

Unica up 16% [Dec 2, 08]

Unica  down 18% [Dec 1, 08]  On a stock bloodbath day

Unica up 15% [Nov 26, 08]

Unica down 11% [Nov 25, 08]

Unica down 13% [Nov 14, 08]

Unica up 26% [Nov 13, 08]

Unica down 12% [Nov 5, 08]

Unica down 13% [Oct 24, 08]

Unica down 11% [Oct 22, 08]

Unica down 11% [Oct 17, 08]

Unica up 18% [Oct 16, 08]

Unica up 10% [Oct 10, 08]

Unica down 10% [Oct 14, 08]

Unica down 11% [Oct 2, 08]

Unica down 11% [Oct 2, 08]

Unica up 12% [Sep 18, 08]

 Unica down 10%  [Mar 6, 08]

Unica up 10% [Feb 13, 08]

Unica down 10% [Jan 4, 08] 

Unica up 15% [Dec 6, 07]

Unidym (Menlo Park, CA)

Nano IPOs. NANOTECHNOLOGY companies, nurtured on billions of dollars in government grants and venture investments through most of this decade, are getting ready to go public. ... NanoGram (Milpitas, CA; no SBIR), Unidym (Menlo Park, CA; no SBIR), NanoDynamics (Buffalo, NY; $1M SBIR).    Unidym is a subsidiary of the Arrowhead Research Corporation, a public investment company that was founded in 2003 to back small companies engaged in nanotechnology research. [James Flanigan, New York Times, Dec 20]

United Devices (Austin TX)

United Devices (Austin TX; no SBIR) which develops software for powerful grids of individual computers, announced today that it has merged with a Chicago company, Univa, which develops related technology, No financial terms were disclosed. [Austin American-Statesman, Sep 18]

Universal Display

Universal Display down 10% [Oct 28, 09]

Universal Display  down 20% [Aug 11, 09]

Universal Display  up 13% [Apr 9, 09]

Universal Display up 14% [Mar 12, 09]

Universal Display up 10% [Mar 10, 09]

Universal Display up 10% [Jan 21, 09]

Universal Display down 13% [Jan 20, 09]

Universal Display up 10% [Jan 6, 09]

Universal Display up 26% [Dec 8, 08]

Universal Display  down 12% [Dec 1, 08]  On a stock bloodbath day

Universal Display up 10% [Nov 26, 08]

Universal Display up 17% [Nov 24, 08]

Universal Display down 15% [Nov 14, 08]

Universal Display up 13% [Nov 13, 08]

Universal Display down 13% [Nov 12, 08]

Universal Display down 10% [Nov 10, 08]

Universal Display down 13% [Oct 15, 08]

Universal Display down 21% [Sep 29, 08]

Universal Display up 13% [Sep 16, 08]

 Organic light-emitting diodes have surpassed fluorescent lights in energy efficiency, according to Universal Display [which] announced it has created an OLED panel that produces 102 lumens, a measure of light output, per watt of electrical power. ...There are plenty of problems still to straighten out with OLEDs before they're practical light sources. The panels dim with a few hundred or thousand hours of use and they're difficult to produce in large quantities. [AP, Jun 23,08]

Universal Display down 12% [Mar 14, 08] after it reported a bigger loss wider than the Street expected.

Universal Display up 10% [Feb 13, 08]

Universal Display down 12% [Jan 8, 08]

Universal Display up 10% on a broker's upgrade. [Jun 19, 07]

Universal Display has not turned a profit. It has lost about $125M since its founding in 1994. ..It has no plans to manufacture products. Instead it will license its [OLED] technology to companies around the world. [Henry Holcomb, Philadelphia Inquirer, reprinted by Seattle Times, Feb 26] Holcomb's hopeful tale never mentions about $8M in SBIR.

Universal Display was up 10% after announcing a big improvement in operational lifetime for a green phosphorescent OLED device [Dec 27, 06]

US Nanocorp (Farmington, CT)

US Nanocorp (Farmington, CT; no previous SBIR)  has a lithium-air battery in which the inspiration for the membrane came from artificial-blood research that produced a material that can carry oxygen. It also has a commercialization partner for its Phase II project in Ultralife Batteries, a major battery manufacturer that pledged $150,000 to help defray some development costs.  [MDA Tech Update, Summer 08]

US Silicones

US Silicones, a start-up supplier of compounded silicone rubber materials for the medical, industrial, automotive and home appliance markets, will locate its manufacturing operations in Fort Wayne. The company, formed by Fort Wayne-based executive management firm Thistle Group, will invest more than $1.1 million to upgrade an existing 15,000 square-foot facility [Indianapolis Star, May 2, 08]

UTRON (Manassas, VA)

Parts from Powder(Mar 20) BMDO SBIR company Utron (Manassas, VA) got some big press - a front page Wall Street Journal (Mar 19)- for its quick powder compaction into small parts. The competition will be fierce though from the many other powder pressers who want the Holy Grail of parts making - instant shape and properties to order. Inventors over the years have thought of many ways to press a powder into some wanted shape. Utron has had only one Phase 2 SBIR (BMDO) and that was for spraying powders rather than compressing them. Pressing powders is the kind of economics-driven SBIR that BMDO likes because it is likely to develop into a market-shelf technology that BMDO's system builders can get a free ride on private capital for their small scale developments done for them. Private capital is happy to oblige for the profit to be made in selling it to everyone except BMDO. Co-founders Dennis Massey and Doug Witherspoon say the phone was ringing yesterday. Doug is also a leader in a DC area tech entrepreneurs' network.

Vala Sciences (San Diego, CA)

The California Institute for Regenerative Medicine, the state stem cell agency, has awarded $1B so far in research money.  SBIR companies got $10M of it.  Bio Time (Berkeley, CA; $300K SBIR)  $4.7M;   Vistagen Therapeutics (Burlingame, CA; $600K SBIR)  $970K; Gamma Medica Ideas  (Northridge, CA; $2.8M SBIR) $950K; Vala Sciences (San Diego, CA; $3M SBIR)  $900K; Invitrogen (Carlsbad, CA; $4M SBIR) $870K SBIR;  Fluidigm (South San Francisco, CA: $1.2M SBIR) [CIRM press release, Oct 28]

Valence Technology (Austin, TX)

Valence Technology (Austin, TX; no SBIR) said it received a $3.1 million order from Smith Electric Vehicles, a British company that makes electric-powered commercial vehicles. Valence, which makes rechargeable batteries, earlier received a $1.4 million order from Smith parent Tanfield Group PLC, which is increasing production of its Smith Newton truck in the United States. [Austin American Statesman, Jan 13, 10]

California investor Carl Berg bought 1.2 million shares of Valence Technology  for $2.5 million in a private placement, according to a regulatory filing. Berg, who is Valence's chairman and co-founder, already was the company's largest shareholder and has provided regular cash infusions. Valence has not made a profit since it was founded in 1989. Valence, which makes lithium-ion batteries, has applied for federal stimulus money to help build an advanced battery plant in Leander. [Austin American Statesman, Jun 16, 09]

ActaCell (Austin, TX; no SBIR) is hardly alone. [CEO] Ott estimates that a dozen companies, many of them startups, are chasing the same goal. Most them are trying to modify the lithium-ion technology now used in many laptop computers and cell phones. One Austin company, Valence Technology Inc., already is making batteries for a variety of vehicles, including the Segway Personal Transporter. ...   and $2 billion in federal funds for advanced battery development just passed by Congress — has sparked a rush of investment in startup battery companies and a surge of interest in promoting more manufacturing of advanced batteries in the U.S. [Kirk Ladendorf, Austin American-Statesman, Mar 9, 08]

Lithium Hope and Despair.  don't expect the standard lithium ion batteries found in most laptops to go away anytime soon.  "It's not going to happen," acknowledged Jim Akridge, who has spent more than 25 years in the battery business. As the CEO of Valence Technology (Austin TX), Akridge runs one of several companies that have developed what they say are safer alternatives to traditional computer batteries. Valence's products use a proprietary chemical mix of lithium and phosphates designed to keep from overheating and catching on fire. ...  Ross Dueber is more confident. He says the battery technology developed by his company, Zinc Matrix Power, will eventually replace lithium ion. But although Zinc Matrix Power has existed since 1997, it hasn't been able to make any inroads with computer makers. Until it does, it probably won't even consider making its batteries on a wide scale, Dueber said. [Bob Keefe, Austin American-Statesman, Oct 17]

Validity Sensors (San Jose, CA)

Validity Sensors, San Jose start-up the builds advanced fingerprint sensors, has raised $20 million in its latest round of venture capital, in what appears to be a formal financial restart of the company. The round included a “substantial investment” from Qualcomm Ventures, according to the company, which suggests the company’s technology will soon be used for mobile phones. [Venturebeat.com, Oct 17]  Venture Beat is Matt Marshall's new site since he left the San Jose Mercury for greener pastures. No SBIRs.'

Vanda Pharmaceuticals (Rockville, MD)

Vanda Pharmaceuticals (founded 2002; Rockville, MD; no SBIR) rose 626% as the FDA approved the company's schizophrenia drug Fanapt.  [Wall Street Journal, May 8, 09]  IPO 2006, 24 employees

Vascular Designs (Silicon Valley)

Goldman tweaked and tweaked. He formed a company, Vascular Designs  (Silicon Valley; who needs SBIR?) headquartered at his home. He lined up angel investors and $1.8 million in seed money. He added about $3 million of his own. He submitted his design to the Food and Drug Administration. It was rejected. Three times. Then in May, he got it: FDA approval. ... It's too early to know how widely the catheter, known as the IsoFlow, will be deployed. Every cancer case is different and Goldman's catheter is not right for all. Goldman's push now is to persuade doctors to try it. [Mike Cassidy, San Jose Mercury News, Nov  23, 09]

VasoGenix Pharmaceuticals (Lenexa, KS)

The Kansas Bioscience Authority announced four grants totaling $4.85 million to help companies in the state. KC BioMediX of De Soto, VasoGenix Pharmaceuticals of Lenexa , Ventria Bioscience of Junction City ($500K SBIR), MGP Ingredients (public) of Atchison. [Kansas City Business Journal, Jul 15, 08]

Vativ Technologies (San Diego, CA)

 San Diego's Entropic Communications has purchased a small semiconductor company whose chips help move high-definition television signals between the TV and other gadgets.   Vativ Technologies (San Diego, CA; no SBIR) had raised about $37M in VC since it was founded in 2001.  [Mike Freeman, San Diego Union-Tribune, Apr 5]

VaxGen

After failing to make an effective HIV vaccine and losing its $877M federal contract to make an anthrax vaccine, VaxGen said its last-ditch effort to save itself through a merger has foundered and its days may be numbered. [Steve Johnson, San Jose Mercury News, Mar 29]

A Shot Too Far. The government killed VaxGen's $877M anthrax vaccine contract because the company had not started the clinical trials. Since VaxGen won the contract two years ago, skeptics have questioned the ability of the company, a small biotechnology business, to deliver on such a large order, as well as the administration’s capacity to properly manage the overall $5.6B program, known as BioShield. [Eric Lipton, New York Times, Dec 20] VaxGen had a $2M SBIR from HHS plus another $700K in SBIR awards. The stock price has dropped 90% in two years. It's a huge leap from a $2M SBIR to $877M with the government customer watching every move.

When FDA halted the VaxGen anthrax vaccine approval train because data submitted by the company are insufficient to determine that the product is stable enough to resume clinical testing, the investors jumped off. Down 56%. [Nov 3, 06]

VaxInnate (New Haven, CT)

E coli bacteria are growing to produce an experimental vaccine against influenza. The company running the experiment, VaxInnate (New Haven, CT; $1.8M SBIR) is working on technology that could derive in only six weeks a new vaccine for the H1N1 swine flu, the virus causing the global scare. Then, in the space of a month, it could turn out 2 billion doses--surpassing the annual production capacity of all flu-shot makers combined. "You could vaccinate everybody on the planet without breaking a sweat," says Alan Shaw, VaxInnate's chief executive and a Merck vaccine veteran. ... still five years away from becoming reality ....  Only a handful of companies, including GlaxoSmithkline and Sanofi-Aventis make flu vaccines, [because] there's no financial incentive to find new methods.  Huge social impact but too little ROI for private investment?  Perfect for government "market failure" programs like SBIR should be. The stopgap solution has been to use government grants to make up for this market failure. Novartis  has got $700 million to build a plant to make flu shots in dog kidney cells. The government aims to have in place within three years the capacity to make 600 million doses of pandemic flu vaccine in six months.  [Matthew Herper, Forbes, May 25, 09]

Vecna Technologies (College Park, MD)

wounded soldiers may be carried off the battlefield in the metallic arms of a BEAR, Battlefield Extraction-Assist Robot, a humanoid-shaped rescue machine being designed by Vecna Technologies (College Park, MD; $3M SBIR so far, mostly a $2.7M Phase 2 unrelated to robots). the robot is built for a variety of lifesaving tasks. ... iRobot is also working on a machine to rescue wounded soldiers. But the iRobot Warrior can do considerably more  [Hiawatha Bray (usually writes for Boston Globe), The Oregonian, May 17]

Veezyon

Los Alamos National Laboratory has approved $250,000 in new funding for four companies from its Venture Acceleration Fund [which] provides investments of up to $100,000 to regional entrepreneurs, companies, investors or strategic partners who use LANL technology or expertise to create or grow regional businesses. Award recipients are chosen based on potential for regional impact, team composition, technical feasibility, market opportunity, and the availability of matching funds or in-kind contributions. Retriever Technology (Santa Fe, NM; no SBIR) will receive $25,000 to upgrade a low-light imaging camera for advanced digital imaging into a more user-friendly and functional form for customer demonstration and evaluation.  Elemetric Instruments (Los Alamos, NM; no SBIR) will get $100,000 to further develop a prototype of an instrument that immediately detects elements in liquids and gases with continuous online, real-time processing. The device, called an element presence detector, is based on LANL technology with potential markets among food and pharmaceutical makers.  STAR Cryoelectronics (Santa Fe, NM; $2M SBIR) will get $75,000 to accelerate development of a high-resolution alpha particle spectrometer to be used in nuclear forensics and nuclear nonproliferation work.  Veezyon (somewhere, NM; no SBIR) will receive $50,000 to improve the technical capabilities of its Veezyon.com Web site — a knowledge-based online video site focusing on shared interest user collaboration.  Since the venture fund was launched in fall 2006, LANL has awarded about $600,000 to six companies, not including the new grants, [New Mexico Business Weekly, Jan 7, 09]

VeinAid

The Massachusetts Medical Device Development Center  reported providing “fast-lane” funding last week to two early-stage companies, MedicaMetrix (Wayland, MA; no SBIR) and VeinAid LLC (Fairfield, CT; no SBIR). MedicaMatrix, founded by Christopher LaFarge, makes the “ProstaGlove,” a disposable glove, with an embedded sensor, used to measure quantitative prostate volume. In addition to funding, the company received clinical trial help and materials development from M2D2. VeinAid, launched by Thomas Kottler, helps relieve varicose vein-associated pain and circulatory issues with its medical device applied externally. The M2D2 funds will aid marketing efforts of the device and assist with venture capital access and mold development.  [Mass High Tech, Nov 26, 08]

Ventria Bioscience (Junction City, KS)

The Kansas Bioscience Authority announced four grants totaling $4.85 million to help companies in the state. KC BioMediX of De Soto, VasoGenix Pharmaceuticals of Lenexa , Ventria Bioscience of Junction City ($500K SBIR), MGP Ingredients (public) of Atchison. [Kansas City Business Journal, Jul 15, 08]

Veracode (Burlington, MA)

Security testing company Veracode (Burlington, MA; founded 2006, no SBIR) has reported a financing agreement with investment firm In-Q-Tel that will allow Veracode grow its subscription-based application security solutions. In-Q-Tel is the venture arm of the CIA. Veracode’s security threat detection service, called SecurityReview, can find security holes from SQL injection, cross-site scripting, malicious code and buffer overflows using its static binary testing technology and never accessing a company’s source code.  [Mass High-Tech, Jul 30, 08]  $19.5 million in funding from lead investors. [company website]

Verax Biomedical (Worcester, MA)

Verax Biomedical (Worcester, MA; $1M SBIR) got clearance from the U.S. Food and Drug Administration to market its test for detecting bacterial contamination in the U.S. blood supply [Mass High Tech, Sep 20, 07]

Verax Biomedical (Worcester, MA; $1M+ SBIR) asked the FDA to approve marketing its Platelet Pan Genera Detection Test for bacterial contaminants in blood.  In 2006, Abbott Diagnostics signed a worldwide exclusive agreement to market and distribute the test, and British Biocell International (BBI) signed a 10-year contract to provide manufacturing. [Mass High Tech, Mar 14]

Verdezyne (previously known as CODA Genomics (Carlsbad, CA)

Verdezyne, previously known as CODA Genomics (Carlsbad, CA; $700K SBIR) which just disclosed a $1.7 million government grant, has raised nearly $3 million of a planned $15.2 million round of venture capital, according to a regulatory filing  ... developing genetic engineering techniques and processes for producing industrial chemicals and fuels from microbes [Xconomy.com, Oct 30, 09]

Verenium (Cambridge, MA)

Cellulosic biofuels technology developer Verenium (no SBIR) is one of two companies slated to receive part of a $40 million grant aimed at fostering the development of small-scale ethanol plants announced today by the DOE.  [Mass High Tech, Jul 16]

Verenium (Cambridge, MA; no SBIR) is starting up a research ethanol plant that runs on agricultural waste and wood products instead of corn. The demonstration-scale plant in Jennings, LA., is designed to run on cellulosic feedstocks such as stems and leaves, which are also known as "nonfood biomass," the alternative energy company said. [Boston Globe, May 28]

Vertex Pharmaceuticals

Life science firms pitch optimism  [CEO] of Alkermes stood before scores of potential investors yesterday and talked about two drugs - for diabetes and opiate dependency - that his Cambridge company expects to get approved in 2010. “This year is going to be a big year,’’ Pops said. ... Henri Termeer defending his leadership at Genzyme  as it scrambles to fix production problems, Biogen Idec’s James C. Mullen avoiding any mention of his recent decision to step down from the company’s top post - the mood was generally upbeat. ...  companies have been raising more money in follow-on offerings than any time in the past decade, about $6 billion in 2009  ...  Another huge market opportunity lies in a drug being developed by Vertex Pharmaceuticals to treat hepatitis C, a largely untreated virus estimated to affect about 3 million Americans and 100 million people globally. “We’re doing a lot to raise awareness of this disease,’’ said new Vertex chief Matthew Emmens.  [Robert Weisman, Boston Globe, Jan 14, 10] from the 28th annual J.P. Morgan Healthcare Conference in San Francisco

Vertex Pharmaceuticals said that it plans to seek regulatory approval of the experimental hepatitis C drug telaprevir as scheduled. [Boston Globe, Jan 12, 10]

Vertex Pharmaceuticals says it intends to offer 10 million shares of its common stock in an underwritten public aiming to raise $442.8 million. [Mass High Tech, Dec 3, 09]

Vertex Pharmaceuticals said a Phase II study showed that twice-daily use of experimental hepatitis C treatment Telaprevir was comparable to three times a day. The dosing change could increase patient convenience and give a competitive advantage versus others developing therapies. [Wall Street Journal, Nov 3] 

With thousands of gastroenterologists and hepatologists converging on Boston for this week’s annual meeting of the American Association for the Study of Liver Diseases - a forum known as “the liver meeting’’ - [Vertex Pharmaceuticals] ...  preparing a show of force to highlight its drug to treat the hepatitis C virus. Researchers for  will make no fewer than three data presentations at the meeting.  [Robert Weisman, Boston Globe, Nov 2, 09]

Vertex Pharmaceuticals said that its hepatitis C treatment telaprevir created an immune system response to the virus in patients who had not been helped by other drugs. [AP, Oct 28, 09]

Vertex Pharma down 10% [Oct 1, 09] after saying it plans to initiate a Phase II clinical trial for its rheumatoid arthritis treatment, which would result in a larger than expected loss for the year. [Wall Street Journal, Oct 2]

Vertex Pharmaceuticals said that it is in line to receive $105 million from Mitsubishi Tanabe Pharma Corp. as a result of an amended agreement involving Vertex's potential Hepatitis C treatment.  [Boston Globe, Jul 30, 09]

Vertex  Pharma down 10% [Mar 2, 09]

Yahoo led a $20M investment into vlingo  (no SBIR), a venture-backed start-up that provides voice-recognition technology for mobile devices. OneSearch is available on Blackberry mobile devices now, and will be rolled out to other products in the future. [Carolyn Johnson, Boston Globe, Apr 2]

VMware

A $360 M return on a two-month investment [in VMware] for a threefold gain. It is the kind of investment that would make a hedge-fund manager's career. ... VMware, not exactly a household name, a $32 billion valuation, nearly as big as the combined market capitalizations of Ford Motor and General Motors. ... But Cisco's investment firepower is aimed at "disruptive technologies," Mr. Hooper says. If that is what VMware really is, ensuring that Cisco gets into the virtual-switching game too may be more valuable than a measly $360 million profit. [Wall Street Journal, Sep 28] How many SBIR "investments" have any hope of becoming a VMware?  If SBIR doesn't focus on disruptive technologies, none.

VMware gained 815%, the biggest percentage rise by a NYSE stock. The shares have now risen 128% since the virtualization-software company went public a week ago.  [Wall Street Journal, Aug 20]

Software company VMware (no SBIR) jumped 76% over its IPO price in first day trading. 

Vorbeck Materials (Jessup, MD)

A startup company hopes later this year to bring to market one of the first products based on the nanomaterial graphene. Vorbeck Materials (Jessup, MD; no SBIR) is making conductive inks based on graphene that can be used to print RFID antennas and electrical contacts for flexible displays. The company, which is banking on the low cost of the graphene inks, has an agreement with the German chemical giant BASF and last month received $5.1 million in financing from private-investment firm Stoneham Partners. [Katherine Bourzac, MIT Tech Review, Aug 17]  

Voxel

3-D Disaster
(May 13) Got a great 3-D image idea? Join the mob. Just don't expect to get rich soon as the Voxel experience shows. Voxel started with the usual enthusiasm in 1988, without SBIR. Venturist Alan Wolfe soon found that a breakthrough isn't the same thing as a commercial product [Forbes, May 18]. Blame went all round. Voxel and its contractor making the prototypes got into a hassle over who was to blame for the unreliable expensive (note the cost element) prototypes. Suits, countersuits, lawyers (never cheap), quickly emptying cash drawer, no revenues, $28M of VC investment gone - all the hallmarks of a disaster. Now that the things might actually work, out of cash to buy the equipment to install in hospitals which are ready to make $60 profit per picture taken. Then the lawsuit went against Voxel and the stock plunged again (61% Monday) to a tiny $2. Meanwhile, DOD is still investing its SBIR in 3-D imagery while the companies lather on the commercial dream-soap. But since DOD is technology, not economics, driven, it will fund the best performer which may be the worst commercial prospect (even if it works). Which is OK as long DOD can fund the entire product development and production (the Cold War paradigm). If, though, YOU want to survive the development, you had better keep an open eye on your market. Or you will be Voxel-ized.

VT Silicon (Atlanta, GA)

VT Silicon (Atlanta, GA; $1.5M SBIR)raised $5.5 million in financing .... last year, raised $3.3 million in a Series A round from Menlo, to design and make prototypes of its “intelligent power amplifier” chips for the next-generation of WiMax mobile devices. [Atlanta Business Chronicle, Nov 19, 08]

WaferGen Biosystems (Fremont, CA)

WaferGen Biosystems (Fremont, CA; no SBIR) raised about $6.2 million in a series of private placements over the summer.  [San Francisco Business Times, Sep 10, 09]

Wakonda Technologies (Fairport, NY)

solar-power startups in particular have seen a three-year surge, from a low of no venture investment in the third quarter of 2005 to a high of more than half a billion dollars in the second quarter of this year.  CaliSolar (Sunnyvale, CA; no SBIR) $13M; Wakonda Technologies (Fairport, NY; $200K SBIR) $9M; Prism Solar Technologies (Lake Katrine, NY; no SBIR) $9M. [lDean Takahashi, MIT Tech Review, S/O 08]

Another thin-film photovoltaic technology developer has joined the ranks of the New England solar community. With $9.5 million in its first round of funding, Wakonda Technologies  (Fairport, NY; $200K SBIR) will set up shop in Medford, after being founded in New York earlier this year. ...According to company statements, Wakonda’s process can increase efficiency of solar cells by up to 30%.  [Mass High Tech, Jul 16]

Wilson Greatbatch

Greatbatch  up 15% [Mar 4, 09] 

Greatbatch up 15% [Nov 5, 08]

Greatbatch announced plans to idle three of its facilities outside its Western New York base. [Business First of Buffalo, Nov 1, 08]  No mention of outsourcing abroad. The company employs about 2,445 workers.

Greatbatch down 11% [Oct 15, 08]

GreatBatch down 11% [Oct 9, 08]

Electrochem, a subsidiary of Greatbatch, said it will relocate 230 employees this week from Canton to a much larger "green" facility in Raynham (above).   [Boston Globe, Aug 14, 08]

Greatbatch down 14% [May 7, 08]

Greatbatch down 16% after lowering its 2007 earnings and revenue guidance by about 12%. [Sep 26, 07]

Greatbatch made a slower pace to a mere $3M profit on $60M revenue and its stock price slipped to only 50 times earnings.  [Oct 05]

Customer Takes Heart. Even the battery supplier Wilson Greatbatch rose 10% when customer Guidant found that its new defibrillator works much better than even hoped for and could end the clinical trials and set off towards production and a doubling of sales. [facts from Christopher O'Connor, smartmoney.com, Nov 21] Note that GB makes money and sells at 1 PE of 41 with an expected profit growth rate of 20% (says the Yahoo consensus). .

In 1956, a University of Buffalo electrical engineer named Wilson Greatbatch was using some early silicon transistors to build a circuit to help the nearby Chronic Disease Research Institute record fast heart sounds. He accidentally installed the wrong resistor into the circuit, and it started to pulse in a recognizable "lub-dub" rhythm. Greatbatch was already aware of a problem called "heart block," in which the organ's natural electrical impulses don't travel properly through the tissue; he quickly realized that this circuit was exactly what was needed to steady these sick hearts. At the time, clunky external cardiac pacemakers existed, but they plugged into wall outlets and had external electrodes that burned the skin. Greatbatch's circuit formed the basis for a painless, implantable device. But he found little enthusiasm for his invention until April 1958, when he met William Chardack, chief of surgery at the Buffalo VA Hospital, who immediately saw the pacemaker's potential. Three weeks later, on May 7, Chardack and Greatbatch successfully implanted their first model in a dog. However, bodily fluids seeped past the electrical tape used to seal the gadget, shorting it out after only four hours. Greatbatch recast the pacemakers in epoxy blocks, and within a year prototypes lasted four months. The team began looking for its first human patient but Greatbatch's employer, Taber Instrument, did not want to take on the potential legal liability of the unproven device. So armed with $2,000, he set out on his own. He hand made 50 pacemakers in a barn workshop, and in April 1960, Chardack implanted the first of 10, seen above, into patients. That year, Minneapolis-based medical electronics firm Medtronic licensed Greatbatch's invention; it remains the top manufacturer of cardiac pacemakers. Greatbatch continued to improve his creation's design and soon developed a corrosion-free lithium battery, helping extend the life of pacemakers from two years to 10. Today, Wilson Greatbatch Technologies of Clarence, NY, is the world's largest manufacturer of implantable lithium batteries. [Technology Review, Sep 01]

Profit in the Heart
(Jul 24)Wilson Greatbatch reported record sales and earnings for the quarter, sales up 41$ and profits up and a profit of $2.6M against a loss in last year's quarter. WB makes batteries for pacemakers and such, GB also palns a secondary issue of 6M shares this week to raise $50M for the company and $150M for exiting shareholders. It is also big enough now to be in the Russell 3000 index.

Wilson Greatbatch has nearly doubled in a month to 400+ times earnings. GB makes power for pacemakers and other implantable devices that keep people ticking. Whether you believe GB is making money depends on how you read the variuous extraordinary items that are an accountant's job security.

Wilson Greatbatch Technologies (Clarence, NY) rose a third from its IPO price after the first week of trading. It raised $80M and now has a market cap of $400M.

Greatbatch Makes the Pace Of the 23 IPOs this week in an again hot IPO market, one, Wilson Greatbatch , a battery company had $1M of SBIR in 1990 and now has 750 employees and revenues of $75M. It will trade on the NYSE. It claims that Over 90% of the pacemakers and implantable cardioverter defibrillators, or ICDs, manufactured worldwide in 1999 used power sources either manufactured by us or produced by third parties under agreements with us to use our patented technology. At its IPO price of $16, it will start with a $290M market cap. The company dates to 1970 when Mr Wilson Greatbatch incorporated it to develop his 1958 invention - the implanatable pacemaker.

Wilson Wolf Manufacturing (New Brighton, MN)

Windlift (Madison, WI)

Three Madison technology companies have been qualified to receive investor tax credits under the state's angel investor and venture fund tax credit programs. The companies are: Windlift LLC, which is developing a wind-powered pump that has a patent pending; Centrose LLC, which is trying to use sugar chemistry to make a variety of existing and failed drugs less toxic and more effective; and Symbiont Web Inc., which is developing software to create a relationship between network, Web and mobile space to promote faster data flows and more stable Internet connections. The tax credit program provides a dollar-for-dollar reduction for state income taxes owed to investors in qualified companies. [Milwaukee Journal-Sentinel, Nov 3, 07] No SBIR for the firms.

Wolf Technical Services (Indianapolis, IN)

Wolf Technical Services (Indianapolis, IN; $1M SBIR), inventor of a high-tech mobile seatbelt for aircraft, has been chosen to design and develop a restraint system for the military....  a U.S. Navy contract valued at $12 million. [Tom Spalding, Indianapolis Star, Sep 22, 09]

Wright Materials Research (Beavercreek, OH)

 the Official Ribbon Cutting Ceremony of Wright Materials Research Company (Beavercreek, OH; $8M SBIR)’s New Scale-Up/Production Building on May 12th with Congressman Hobson and other public officials and dignitaries joining this grand celebration. [Dayton Daily News, May 9, 08] It helps to live near the flagpole.

Xanthus Pharmaceuticals

Xanthus Pharmaceuticals (Cambridge MA; $2.5M SBIR) won orphan drug approval by the European Commission for its acute myeloid leukemia treatment  [Mass High Tech, Oct 26]

Xanthus Pharmaceuticals $25 M in an equity financing. Xanthus Life Sciences (same address) had one $2.4M Phase 2 SBIR.

Xcellerex (Marlborough, MA)

Xcellerex (Marlborough, MA; no SBIR) a provider of manufacturing systems for biotherapeutics and vaccines, has begun a Phase 1 clinical trial of its yellow fever vaccine, XRX-001. ... In 2007, Xcellerex pulled in $20 million in a second round of financing .. Series C round of financing came later in 2007 with an investment of $31 million. [Mass High Tech, Jan 13, 10]

Xenomics (NY, NY)

Xenomics (NY, NY; no SBIR) accused Sequenom of deliberately doctoring test data on what was considered a promising Down syndrome test. Small firm Xenomics, which has a pending lawsuit against Sequenom, says it gave the company an exclusive license on urine-testing technology for fetal testing based on the promise of the Down syndrome test. Now it wants out of the agreement and is also seeking up to $300 million in damages. [Thomas Kupper, San Diego Union Tribune, Dec 18, 09] 

Xenoport

XenoPort up 10% [Nov 6, 09]

XenoPort down 13% [Oct 28, 09]

XenoPort up 26% [Sep 17, 09] after GlaxoSmithKline and Xenoport Inc. said Thursday their developing neuropathic pain treatment candidate met its key goal of lowering pain intensity in a midstage study. [AP, Sep 17]

Xenoport down 10% [Jul 8, 09]

XenoPort said it will sell 2.5 million shares of its common stock, increasing the number of outstanding shares by more than 9 percent. ...  The proceeds will go to fund research and development of its drug candidates, possible sales and marketing activities and for general corporate purposes, the company said in a regulatory filing. [AP, Jul 7, 09]

XenoPort up 12% [Jun 2, 09]

Xenoport  down 16% [Apr 27, 09]  the company and large-cap GlaxoSmithKline said their drug Solzira failed to meet the goals of a Phase 2 study to treat loss of feeling in the extremities of diabetics. [Wall Street Journal, Apr 28, 09]

XenoPort  up 11% [Mar 23, 09]

Xenoport down 11% [Mar 5, 09]

XenoPort  down 35% [Dec 2, 08]  as results from a midstage trial comparing the tablet XP19986 with a placebo for the treatment of a reflux disease did not reach statistical significance.  [AP, Dec 2]

Xenoport up 14% [Nov 13, 08]

XenoPort down 13% [Nov 10, 08] and large-cap GlaxoSmithKline said their new drug application for Solzira, a treatment for moderate-to-severe primary restless legs syndrome, has been withdrawn.  [Wall Street Journal, Nov 11]

Xenoport up 13% [Oct 16, 08]

Xenoport up 16% [Oct 13, 08]

Xenoport down 11% [Oct 9, 08]

Xenoport down 10% [Sep 17, 08]

Xenoport up 11% on news of a drug deal with Glaxo. [Feb 8, 07]

Xidex (Austin, TX)

Xidex (Austin, TX; $3M SBIR) won a $750,000 DOE contract to develop tiny [nanotechnology] devices to improve the resolution of powerful high-tech microscopes.  [Austin American-Statesman, Dec 10]

Xitronix (Austin, TX)

From the Texas Emerging Technology Fund, Image Trends (Austin, TX; no SBIR) which develops image correction and enhancement products for commercial and amateur photographers will receive $1 million, and RFMicron (Austin, TX; no SBIR) $250,000 to speed development of its microchip technology  [Lori Hawkins, Austin American-Statesman, Jul 14, 08]  Og ten central TX companies fed from the fund, only one has failed so far: Nanocoolers (no SBIR) Tried to create a thermoelectric cooling system that would help cool semiconductors. Closed in 2007. The others: Molecular Imprints Inc. Nanotechnology company that makes advanced equipment used in producing computer chips, disk  drives and other products. Monebo Technologies (no SBIR) Heart monitoring device called CardioBelt that enables users to obtain their own electrocardiogram while at home.  Quantum Logic Devices  ($1+M SBIR, moved from NC) Developing a system that uses single-electron devices to analyze  DNA, protein and other molecular interactions. Receptor Logic Ltd. (no SBIR) Developing antibodies to improve understanding of the immune system and lead to better drugs and vaccines. Xitronix (no SBIR) Developing advanced semiconductor testing technology. XTreme Power (no SBIR) Developing electrical storage systems that are used to cut energy bills for commercial and industrial plants.

Xitronix (Austin, TX; no SBIR) won a $500,000 grant from the Texas Emerging Technology Fund to develop an advanced semiconductor testing technology. The year-and-a-half-old Austin startup uses a technology called photo-reflectance to quickly identify whether wafers being processed inside a chip factory are defective. The company says its technology can save chip manufacturers time and money by finding and fixing process problems more rapidly. ... partnering with the Austin Technology Incubator, the Nanomaterials Application Center at Texas State University and the Sematech research consortium in its technology and business development. .. already has received $500,000 from private investors, and will use the state grant to accelerate commercialization of its system for chip factories that process 12-inch silicon wafers. [Austin American-Statesman, Apr 4, 08]

Xoma (Berkeley, CA)

Xoma will receive $6 million from Arana Therapeutics Ltd. for the use of the company’s research and development technologies, including a new antibody library that could make it easier for Arana to find rare and unique antibodies.  [San Francisco Business Times, Sep 9, 09]

Xoma (Berkeley, CA; $500K SBIR) won a $65 million, six-year contract from the National Institute of Allergy and Infectious Diseases to study a treatment for botulism poisoning. ... the third contract, totaling $100 million, awarded to -based Xoma from the unit of the National Institutes of Health.   [East Bay Business Times, Sep 9, 08] 

XSunX(Aliso Viejo, CA)

Most solar panels are bulky, pricey, and difficult to install. But imagine if you could turn windows -- or entire skyscrapers -- into solar power generators. That’s the goal of XsunX, http://www.xsunx.com/ a startup in Aliso Viejo, Calif., that has invented a way to stick semitransparent solar cells on plastic film, which manufacturers can use to transform ordinary windows into PowerGlass. “It’s like a power-plant skin on a building,” says XsunX CEO Tom Djokovich. Why no SBIRs yet reported?  Perhaps because the founder/CEO has a long business track record that would satisfy investors seeking innovative enterprises with good (think markets and profits) management.

Xtalic (Marlborough, MA)

Nanotech firm Xtalic (Marlborough, MA; no SBIR) raised $10M in a second round. [Mass High Tech, Nov 3, 08]

Xtent

Stent-maker Xtent (no SBIR) was the fifth company to go public this week. [Jan 07]

Xtreme Power (Kyle, TX)

Xtreme Power (Kyle, TX; no SBIR) won a $2M grant from the Texas Emerging Technology Fund to speed the commercialization of its electrical storage systems that are used to cut energy bills for commercial and industrial plants. [Austin Statesman-American, Mar 21]

Xunlight (Toledo, OH)

startup Xunlight (Toledo, OH; no SBIR) has developed a way to make large, flexible solar panels. It has developed a roll-to-roll manufacturing technique that forms thin-film amorphous silicon solar cells on thin sheets of stainless steel. Each solar module is about one meter wide and five and a half meters long. [Prachi Patel, MIT Tech Review, Jun 4, 09]

Y-Carbon (King of Prussia, PA)

As a graduate student in materials science at Drexel University, Ranjan Dash used a novel chemical recipe to engineer nanoscopic pores into the carbon materials used in ultracapacitors. The tiny pores, whose size can be tuned with subnanometer precision, provide more surface area for charged particles to stick to, doubling the amount of energy the ultracapacitors can hold. Dash cofounded Y-Carbon (King of Prussia, PA; no SBIR) to commercialize the technique, and he now serves as its chief technology officer. He says that his company has already developed a prototype ultracapacitor. [Neil Savage, MIT Tech Review, Sep/Oct09]

Yurie (Landover, MD)

[Jeong] Kim left Allied Signal and created Yurie (Landover, MD) in 1992 as an 8(a) company. A company spokesman said Yurie has never sought or received any government contracts through the programs because Kim "does not believe in" such government help. [Washington Post, Apr 28] Yurie makes video transmission equipment principally for government, employs 240 people, and Kim just sold it for $1B to Lucent. No SBIR. Yep, those small companies sure need SBIR to get into government procurement. Kim keeps $500M of the proceeds.

Z

Z Corp. plucked a futuristic technology from the labs of MIT - a printer that can produce three-dimensional objects, in color - and built it into a $60 million-a-year business. Companies like Reebok, Raytheon, and Avid Technology use the printers to create prototypes of new products, quickly and inexpensively.  ...."3-D printing should migrate anywhere people are using 3-D data," Kawola says, envisioning the new venture as something that could generate "$20 million, $30 million, $50 million in revenue" for the company.... founded in 1994 to commercialize a technology developed at MIT, which uses standard ink-jet printer heads - the kind you'd find in any home printer - to spray a glue or binder and colored pigment over a thin layer of a powdery substance. ... In 2005, acquired by Contex Scanning Technology, a Danish company, ... In turn, Contex was sold to a private equity firm in Sweden last year, for about $240 million. [Scott Kirsner, Boston Globe, Sep 7]

ZafGen (Cambridge, MA)

ZBB Energy (Menomonee Falls, WI)

ZBB Energy  (Menomonee Falls, WI; no SBIR)  that builds high-efficiency fuel cells, will provide the energy storage system for what could be a high-profile exhibit at this summer's Olympic Games in Beijing, the firm said ... raised about $20M in a public stock offering last June  [Rick Romell, Milwaukee Journal-Sentinel, Apr 3, 08]

ZBB Energy (Menomonee Falls, WI; no SBIR) went public for $20M.   ZBB says its zinc-bromine batteries store and discharge electricity more efficiently than traditional lead-acid batteries and can be combined easily in modules to meet various power requirements. The 9-year-old company has done only limited manufacturing. It lost $2.9 million in fiscal 2006 and expects to continue losing money through mid-2008, according to its prospectus. [Milwaukee Journal Sentinel, Jun 19]

ZBB Energy (Menomonee Falls, WI) seeks $15M public stock offering.  A 35-employee basically Australian small company holds a proprietary position on zinc-bromine batteries. [Rick Romell, Milwaukee Journal-Sentinel, Jan 4]

ZeaChem (Golden, CO)

ZeaChem (Golden, CO; one SBIR) has won a $25 million federal grant to build an advanced biofuel plant in Boardman [OR] that converts poplar trees to motor vehicle fuel. ... one of 19 nationwide to receive $564 million in grants from federal economic stimulus money [Scott Learn, The Oregonian, Dec 4, 09]

Ze-gen

Clean energy company Ze-gen Inc., which makes gasification technology to convert municipal waste streams into synthesis gas, says that it has closed on $2.5M in venture debt [Mass High Tech, Jan 10]

ZenBio (Research Triangle Park, NC)

ZenBio (Research Triangle Park, NC; founded in 1995; at least $1.4M SBIR) received a $1.88 million Phase II SBIR grant from the National Institutes of Health to develop a unique tool for cancer, obesity and diabetes research.  [Raleigh News & Observer, Jan 28, 09]

Zilker Labs (Austin, TX)

Zilker Labs (Austin TX; no SBIR) a five-year-old chip company, raised $10M in its fourth venture investment round.  Zilker says its chips give engineers an easy-to-use method of controlling the delivery of precise amounts of electrical power inside the circuit boards that control complex systems such as servers, storage systems, communications equipment and industrial control equipment. The company says it is working on design projects with its 50 or so active customers. [Austin American-Statesman, Oct 3]Zilker raises $8M. Semiconductor startup Zilker Labs http://www.zilkerlabs.com/  has raised $8 million in its third round of venture capital investment funding to pay for high-volume production of its first chip and development of new products.  ... Zilker develops chips that precisely manage electrical power within advanced communications equipment, servers and other electronics products. The company says its products will simplify and speed the design of complex circuit boards. [Austin Statesman-American, May 11]

Zinc Matrix Power (Camarillo, CA)

Army's venture venture.  The Army's VC (OnPoint Tech) current investment portfolio : A123 Systems (Boston, MA; $750K SBIR, IPO 2009) advanced Lithium-Ion based cells for rechargeable battery packs;  Atraverda (UK) advanced bi-polar battery electrodes for rechargeable batteries;  Integrated Fuel Cell Technologies  (Burlington MA; no SBIR) next generation fuel cell systems for portable devices;  Nanosolar (Palo Alto, CA; $1.7M SBIR) thin-film solar technology for roll-to-roll printing of solar cells on flexible substrates,   PowerGenix (San Diego, CA; no SBIR) next-generation rechargeable batteries; Power Precise (Herndon, VA; no SBIR) a fabless semiconductor company specializing in battery management devices; Ultra Cell (Livermore, CA; no SBIR) integrated fuel cell systems; Zinc Matrix Power (Santa Barbara, CA; no SBIR) high-performance rechargeable alkaline battery technology for commercial and military markets;  Akermin (St Louis, MO; no SBIR) portable fuel cells based on its proprietary “Stabilized Enzyme Biofuel Cell” SEBC™ technology; Superprotonic (Pasadena CA; $200K SBIR) solid acid fuel cell.  [defense-ventures.com]  No surprise that a VC, even one doing it for the government, sees tech opportunity much different than does Army SBIR. I note that the three outside trustees (of five trustees) of OnPoint are a DOD political appointee, and entrepreneur/attorney, and Paul Gompers from Harvard Business School who with Josh Lerner publish a lot of venture research. Lerner did a lot of SBIR study until, I presume, he gave up on SBIR's ever being anything but a political handout.

Lithium Hope and Despair.  don't expect the standard lithium ion batteries found in most laptops to go away anytime soon.  "It's not going to happen," acknowledged Jim Akridge, who has spent more than 25 years in the battery business. As the CEO of Valence Technology (Austin TX), Akridge runs one of several companies that have developed what they say are safer alternatives to traditional computer batteries. Valence's products use a proprietary chemical mix of lithium and phosphates designed to keep from overheating and catching on fire. ...  Ross Dueber is more confident. He says the battery technology developed by his company, Zinc Matrix Power, will eventually replace lithium ion. But although Zinc Matrix Power has existed since 1997, it hasn't been able to make any inroads with computer makers. Until it does, it probably won't even consider making its batteries on a wide scale, Dueber said. [Bob Keefe, Austin American-Statesman, Oct 17]

An alternative to lithium-ion batteries--silver-zinc batteries--could add several hours to the time that laptops can run between charges, while at the same time avoiding the safety issues that have resulted in the recent massive recalls of laptop batteries, says Zinc Matrix Power (Camarillo, CA). .. has now demonstrated the silver-zinc in a laptop ...  plans to begin distributing test batteries to manufacturers early next year, focusing on laptops and cell phones. [Kevin Bullis, MIT Tech Review, Oct 11]  ZMP got some of its capital from the Army trial VC program run by On Point.

Zinc Matrix Power, which makes a silver-zinc battery that lasts twice as long as lithium-ion batteries of the same size,  closed $7 M in VC funding, suggesting there could soon be more portable power options for notebook computers and other devices. ... to establish and staff a pilot production facility in Camarillo, California. .. currently testing its batteries with the U.S. Army and will release batteries to be tested on notebook computers later this year. [Red Herring, Apr 14]

Ziopharm Oncology (NY, NY)

Ziopharm Oncology (NY, NY; no SBIR) is offering about 15.5 million common shares and warrants to buy 7.7 million shares in a public offering. ... to net about $45M ... for clinical development of its product candidates and other corporate purposes.  [AP, Dec 4, 09]

Zosano Pharma (Fremont, CA)

Zosano Pharma (Fremont, CA; no SBIR), which focuses on products based on its transdermal delivery technology, said Tuesday it closed a $30 million round of funding. ...  support the ongoing scale-up for Phase 3 clinical development and manufacturing readiness for Zosano’s lead program, a rapid delivery patch for the treatment of osteoporosis. [Silicon Valley/San Jose Business Journal, Jul 7, 09]

ZPower (Camarillo, CA)

ZPower  (Camarillo, CA; no SBIR) , included in the list of GoingGreen 100 Top Private Companies, has recently announced that the company is releasing the hotly anticipated silver-zinc batteries in 2009.  .... ZPower claims that silver-zinc batteries have 40-percent longer lifespan than other current batteries in the market. Silver-zinc is also reportedly more chemically stable than lithium-ion. [Mariella Moon, GoodCleanTech, Aug 22]

Zumobi

Zenzui, which was spun out of Microsoft, has been renamed Zumobi. The Seattle-based startup said the name better represents the business it's in -- mobile.  On Dec. 14, it plans to launch a beta version of its mobile-phone software. ... launched in March after spinning off from Microsoft and raising $12M  [Seattle Times, Nov 17]

Zygo

Zygo (one Phase 1 SBIR) is among the more successful Connecticut-bred tech firms, with 375 local employees and a solid market niche. Its merger [with Electro Scientific (no SBIR)] — which is being contested in court by a shareholder group — would leave Zygo under the control of another company. But that is the best plan for nurturing the business, Zygo officials said. ... The deal is typical of a market where tech companies are searching for growth and capital, said Matthew Nemerson, president and CEO of the Connecticut Technology Council. [Kenneth St Onge, Hartford Courant, Dec 19, 08]

ZymoGenetics

ZymoGenetics said its stock offering of 14 million shares was priced at $6 per share, ...  its net proceeds will be approximately $79 million  [Seattle Times, Jan 9, 10]

Zymo Genetics down 10% [Jan 7, 10]

ZymoGenetics said it will sell 12 million shares of stock [for $80M] in a public offering, using the proceeds to expand sales of its sole product and to continue its R&D efforts.  [Seattle Times, Jan 7, 10]

Bayer has received approval to market ZymoGenetics' only product, Recothrom, in Canada. The milestone entitles ZymoGenetics to a $3.5 million payment.  [Seattle Times, Dec 16. 09]

Bayer has withdrawn its application to market the ZymoGenetics drug Recothrom in Europe [Seattle Times, Dec 14, 09]

ZymoGenetics has struck a deal with its former parent from Denmark, Novo Nordisk, that will give Novo a jumpstart on its quest to become a bigger player in autoimmune diseases. Novo said it agreed to pay $24 million in upfront cash, and milestone payments worth as much as $157.5 million over time to ZymoGenetics [Luke Timmerman, xconomy Seattle, Dec 8, 09]

Zymo Genetics up 11% [Nov 6, 09]

ZymoGenetics said rival King Pharmaceuticals has obtained a temporary restraining order barring the Seattle-based biotechnology company from making certain claims regarding how its only marketed product, Recothrom, compares to the competing drug from King. [Seattle Times, Nov 5, 09]

ZymoGenetics said that it started a midstage study on a potential hepatitis C treatment, triggering a $70 million payment from its partner, Bristol-Myers Squibb. The Seattle company is studying PEG-Interferon lambda, called IL-29, as a potential combination treatment with the hepatitis C drug ribavirin. It could receive up to $1.12 billion in the collaboration with Bristol-Myers. [Seattle Times, Oct 28, 09]

ZymoGenetics said Merck Serono has discontinued mid-stage studies of the Seattle company's drug atacicept in multiple sclerosis, after one study showed patients did worse with the treatment than without it.  [Seattle Times, Sep 28, 09]

ZymoGenetics  said that its drug atacicept “did not meet the pre-specified level of disease control activity” to support further testing in recent clinical trials.  [Puget Sound Business Journal (Seattle), Sep 10, 09]

Zymo Genetics up 19% [Jul 20, 09] in sympathy with tripling of Human Genome Sciences's after success of their Benlysta drug in the treatment of lupus.  [tickerspy.com, Jul 20]

ZymoGenetics  up 12% [May 11, 09]

Four days after announcing it will lay off more than 160 employees and will discontinue some of its research efforts, ZymoGenetics said it will license eight of its “noncore assets” to Seattle Life Sciences (no SBIR).  [Puget Sound Business Journal, May 4]

ZymoGenetics will slash its workforce by one third, cutting 161 jobs, as it narrows its research and development efforts, the Seattle biotechnology company said today.  The company expects to save $30 million a year in operating expenses, it said in a statement. ZymoGenetics said it will continue to expand the market for its sole approved product, the blood-clotting compound Recothrom Thrombin, but will "focus all future research efforts in immunology, its core strength."  [Seattle Times, Apr 29, 09]

Zymo Genetics  up 12% [Mar 23, 09]

Zymo Genetics up 15% [Mar 12, 09]

Zymo Genetics up 10% [Mar 10, 09]

ZymoGenetics down 12% [Mar 5, 09]

Bristol-Myers Squibb said it will team with ZymoGenetics to develop a hepatitis C treatment, in a deal that could eventually bring ZymoGenetics more than $1 billion.  [Wall Street Journal, Jan 13, 09]  up 26%

ZymoGenetics up 14% [Dec 12, 08]

ZymoGenetics  down 11% [Dec 1, 08] On a stock bloodbath day

Zymo Genetics down 10% [Nov 14, 08]

ZymoGenetics up 14% [Nov 13, 08]

ZymoGenetics down 15% [Nov 12, 08]

ZymoGenetics said that quarterly sales for its only commercial product increased by 27 percent but still fell short of expectations, spurring a new strategy to ramp up sales. [Angel Gonzalez, Nov 5, 08]

Zymo genetics up 17% [Nov 3, 08]

Zymo Genetics up 18% [Oct 30, 08]

ZymoGenetics shares fell 29% after a trial of its drug to treat kidney disease in lupus patients was discontinued by Merck Serono because of high risk of infection. [Seattle Times, Oct 27, 08]

Zymogenetics up 18% [Oct 16, 08]

Zymogenetics up 11% [Oct 13, 08]

Seeking to reduce the rate at which it burns cash, ZymoGenetics is handing off the development and commercialization of one of its key compounds to partner Merck Serono, the company is expected to announce today.  [Angel Gonzalez, Seattle Times, Sep 3, 08]

In a move to raise cash without selling more of its battered stock, ZymoGenetics announced Monday a deal to borrow up to $100 million from investment fund Deerfield Management. [Seattle Times, Jul 1, 08]

Facing a tough stock market and Wall Street skepticism over the recent launch of its first commercial product, ZymoGenetics (Seattle, WA; <$1M SBIR in the 1980s)  is reining in spending by cutting 80 jobs  [Angel Gonzalez, Seattle Times, Feb 14]

ZymoGenetics down 17% [Jan 18, 08]

ZymoGenetics (Seattle, WA; $800K SBIR) fell 7% as a Bank of America analyst downgraded the company ...raised concerns about the lead product, rThrombin, expected to be approved next month by the Food and Drug Administration. ... the area's largest independent biotech, also announced the start of a midstage clinical trial to test one of its cancer-fighting therapies on patients with metastatic melanoma.  [Seattle Times, Dec 19, 07]

Zymogenetics up 10%.  [Aug 8, 07]

ZymoGenetics up 12% [Aug 2, 07] after a Banc of America Securities analyst upgraded the stock to "Buy" on hopes the company's drug rHThrombin is near federal approval.